Active ingredient combinations having insecticidal and acaricidal properties

ABSTRACT

The novel active ingredient combinations which consist of the compounds of the formula (I) in combination with further active insecticidal ingredients (II) are very suitable for control of animal pests such as insects and/or unwanted acarids.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser. No. 13/161,960, filed Jun. 16, 2011, which claims priority to EP 10166439.9 filed Jun. 18, 2010 and U.S. 61/356,224 filed Jun. 18, 2010, the contents all of which are incorporated herein by reference in their entireties.

BACKGROUND

1. Field of the Invention

The present invention relates to novel active ingredient combinations which consist of the compounds of the formula (I) in combination with further active insecticidal ingredients (II) and are very suitable for control of animal pests such as insects and/or unwanted acarids.

2. Description of Related Art

Some of the compounds of the formula (I) are known from WO 2007/144100 and their insecticidal action has been described. The active ingredients specified in this description by their common name are known, for example, from “The Pesticide Manual” 14th ed., British Crop Protection Council 2006, and the website http://www.alanwood.net/pesticides.

However, the acaricidal and/or insecticidal efficacy and/or the activity spectrum and/or the compatibility of the known compounds with plants, especially with respect to crop plants, is not always adequate.

SUMMARY

It has now been found that active ingredient combinations comprising the compounds of the general formula (I)

in which

-   R¹ is hydrogen, amino, hydroxyl or in each case optionally     C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl or C₃-C₆-cycloalkyl, where     the substituents may each independently be selected from halogen,     cyano, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio,     C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, (C₁-C₄-alkoxy)carbonyl,     C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino or     (C₁-C₄-alkyl)C₃-C₆-cycloalkylamino, -   R² is hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl,     C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkylamino,     di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, C₁-C₆-alkoxycarbonyl     or C₁-C₆-alkylcarbonyl, -   R³ is hydrogen or in each case optionally mono- or polysubstituted     identically or differently, C₁-C₆-alkyl, C₁-C₆-alkoxy,     C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₁₂-cycloalkyl,     C₃-C₁₂-cycloalkyl-C₁-C₆-alkyl, where the substituents may each     independently be selected from amino, C₃-C₆-cycloalkylamino,     halogen, cyano, carboxyl, carbamoyl, nitro, hydroxyl, C₁-C₆-alkyl,     C₁-C₆-haloalkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl,     C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylcarbonyl, C₃-C₆-trialkylsilyl or a     saturated or partly saturated heterocyclic ring, an aromatic or     heteroaromatic ring or a saturated, partly saturated or aromatic     heterobicyclic ring, where the ring or ring system is optionally     mono- or polysubstituted identically or differently by SF₅, halogen,     cyano, nitro, hydroxyl, amino, carboxyl, carbamoyl, aminosulphonyl,     C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₆-haloalkyl,     C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl,     C₁-C₄-alkylsulphonyl, C₁-C₄-alkylsulphimino,     C₁-C₄-alkylsulphimino-C₁-C₄-alkyl,     C₁-C₄-alkylsulphimino-C₂-C₅-alkylcarbonyl, C₁-C₄-alkylsulphoximino,     C₁-C₄-alkylsulphoximino-C₁-C₄-alkyl,     C₁-C₄-alkylsulphoximino-C₂-C₅-alkylcarbonyl, C₁-C₆-alkoxycarbonyl,     C₁-C₆-alkylcarbonyl, C₃-C₆-trialkylsilyl, benzyl C₂-C₆-alkenyl,     C₂-C₆-alkynyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl,     C₃-C₆-halocycloalkyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl,     C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino,     C₃-C₆-cycloalkylamino, or a 3- to 6-membered ring, where the ring     may optionally be substituted by C₁-C₆-alkyl, halogen, cyano, nitro,     halo(C₁-C₆)-alkyl, C₁-C₆-alkoxy or halo(C₁-C₆)-alkoxy, or -   R³ is C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylcarbonyl,     C₁-C₆-alkylaminocarbonyl or di(C₁-C₆)alkylaminocarbonyl, or -   R³ is additionally a mono- or polysubstituted identically or     differently, 5- or 6-membered aromatic or heteroaromatic ring, a 4,     5- or 6-membered partly saturated ring or saturated heterocyclic     ring, or a saturated, partly saturated or aromatic heterobicyclic     ring which may optionally contain one to three heteroatoms from the     group of O, S and N, where the substituents are each independently     selected from SF₅, halogen, cyano, nitro, hydroxyl, amino, carboxyl,     carbamoyl, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy,     C₁-C₆-haloalkyl, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio,     C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-alkylsulphimino,     C₁-C₄-alkylsulphimino-C₁-C₄-alkyl,     C₁-C₄-alkylsulphimino-C₁-C₅-alkylcarbonyl, C₁-C₄-alkylsulphoximino,     C₁-C₄-alkylsulphoximino-C₁-C₄-alkyl,     C₁-C₄-alkylsulphoximino-C₂-C₅-alkylcarbonyl, C₁-C₆-alkoxycarbonyl,     C₁-C₆-alkylcarbonyl, C₃-C₆-trialkylsilyl, C₂-C₆-alkenyl,     C₂-C₆-alkynyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl,     C₃-C₆-halocycloalkyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl,     C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino,     C₃-C₆-cycloalkylamino, or a 3- to 6-membered ring, where the ring     may optionally be substituted by C₁-C₆-alkyl, halogen, cyano, nitro,     halo(C₁-C₆)-alkyl, C₁-C₆-alkoxy or halo(C₁-C₆)-alkoxy, -   R² and R³ may be joined to one another via two to six carbon atoms     and form a ring which optionally additionally contains a further     nitrogen, sulphur or oxygen atom and may optionally be mono- to     tetrasubstituted by C₁-C₂-alkyl, C₁-C₂-haloalkyl, halogen, cyano,     amino C₁-C₂-alkoxy or C₁-C₂-haloalkoxy, -   R², R³ together are additionally ═S(C₁-C₄-alkyl)₂,     ═S(O)(C₁-C₄-alkyl)₂, -   R⁴ is hydrogen, halogen, cyano, nitro C₁-C₄-alkyl, C₁-C₄-haloalkyl,     C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₁-C₄-alkoxy,     C₁-C₄-haloalkoxy, SF₅, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl,     C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl,     C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino,     C₃-C₆-cycloalkylamino, (C₁-C₄-alkoxy)imino,     (C₁-C₄-alkyl)(C₁-C₄-alkoxy)imino,     (C₁-C₄-haloalkyl)(C₁-C₄-alkoxy)imino or C₃-C₆-trialkylsilyl, or

two R⁴ via adjacent carbon atoms form a ring which is —(CH₂)₃—, —(CH₂)₄—, —(CH₂)₅—, —(CH═CH—)₂—, —OCH₂O—, —O(CH₂)₂O—, —OCF₂O—, —(CF₂)₂O—, —O(CF₂)₂O—, —(CH═CH—CH═N)— or —(CH═CH—N═CH)—,

two R⁴ via adjacent carbon atoms additionally form the following fused rings which are optionally mono- or polysubstituted identically or differently, where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₃-C₆-halocycloalkyl, halogen, C₁-C₆-alkoxy, C₁-C₄-alkylthio(C₁-C₆-alkyl), C₁-C₄-alkylsulphinyl(C₁-C₆-alkyl), C₁-C₄-alkylsulphonyl(C₁-C₆-alkyl), C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino or C₃-C₆-cycloalkylamino,

-   n is 0 to 3, -   R⁵ is C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl,     C₁-C₆-halocycloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl,     C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl,     C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl,     C₁-C₄-haloalkylsulphonyl, halogen, cyano, nitro or     C₃-C₆-trialkylsilyl, -   Q_(X) is an optionally singly or multiply, identically or     differently R⁷-substituted, aromatic or heteroaromatic 5- to     6-membered ring which may contain 1-3 heteroatoms from the group of     N, S, O, -   A is optionally mono- or polysubstituted —(C₁-C₆-alkylene)-,     —(C₂-C₆-alkenylene)-, —(C₂-C₆-alkynylene)-,     —R⁸—(C₃-C₆-cycloalkyl)-R⁸—, —R⁸—O—R⁸—, —R⁸—S—R⁸—, —R⁸—S(═O)—R⁸—,     —R⁸—S(═O)₂—R⁸—, —R⁸—N(C₁-C₆-alkyl)-R⁸—, —R⁸—C═NO(C₁-C₆-alkyl)-R⁸,     —CH[CO₂(C₁-C₆-alkyl)-, —R⁸—C(═O)—R⁸, —R⁸—C(═O)NH—R⁸,     R⁸—C(═O)N(C₁-C₆-alkyl)-R⁸, —R⁸—C(═O)NHNH—R⁸—,     —R⁸—C(═O)N(C₁-C₆-alkyl)-NH—R⁸—, —R⁸—C(═O)NHN(C₁-C₆-alkyl)-R⁸,     —R⁸—O(C═O)—R⁸, —R⁸—O(C═O)NH—R⁸, —R⁸—O(C═O)N(C₁-C₆-alkyl)-R⁸,     —R⁸—S(═O)₂NH—R⁸, —R⁸—S(═O)₂N(C₁-C₆-alkyl)-R⁸, —R⁸—S(C═O)—R⁸,     —R⁸—S(C═O)NH—R⁸, —R⁸—S(C═O)N(C₁-C₆-alkyl)-R⁸, —R⁸—NHNH—R⁸,     —R⁸—NHN(C₁-C₆-alkyl)-R⁸, —R⁸—N(C₁-C₆-alkyl)-NH—R⁸,     —R⁸—N(C₁-C₆-alkyl)-N(C₁-C₆-alkyl)-R⁸, —R⁸—N═CH—O—R⁸,     —R⁸—NH(C═O)O—R⁸, —R⁸—N(C₁-C₆-alkyl)-(C═O)O—R⁸, —R⁸—NH(C═O)NH—R⁸,     —R⁸—NH(C═S)NH—R⁸, —R⁸—NHS(═O)₂—R⁸, R⁸—NH—R⁸, R⁸—C(═O)—C(═O)—R⁸,     R⁸—C(OH)—R⁸, R⁸—NH(C═O)—R⁸, R⁸-Qz-R⁸, R⁸—C(═N—NR′₂)—R⁸,     R⁸—C(═C—R′₂)—R⁸ or —R⁸—N(C₁-C₆-alkyl)S(═O)₂—R⁸,

where the substituents may each independently be selected from halogen, cyano, nitro, hydroxyl, C1-C6-alkyl, C1-C6-alkoxy, halogen-C1-C6-alkyl, amino, (C1-C6-alkyl)amino, di(C1-C6-alkyl)amino, C3-C6-cycloalkyl

where —(C3-C6-cycloalkyl)- in the ring may optionally contain 1 to 2 heteroatoms selected from the group of N, S, O,

-   R⁸ is linear or branched —(C₁-C₆-alkylene)- or a direct bond,

where two or more R⁸ are independently linear or branched-(C₁-C₆-alkylene)- or a direct bond,

for example R⁸—O—R⁸— is —(C₁-C₆-alkylene)-O—(C₁-C₆-alkylene)-, —(C₁-C₆-alkylene)-O—, —O—(C₁-C₆-alkylene)-, or —O—,

where R′ is alkyl, alkylcarbonyl, alkenyl, alkynyl, which may optionally be mono- or poly-halogen-substituted,

-   Qz is a 3- to 4-membered, partly saturated or saturated, or a 5- to     6-membered, partly saturated, saturated or aromatic ring or a 6- to     10-membered bicyclic ring system,

where the ring or bicyclic ring system may optionally contain 1-3 heteroatoms from the group of N, S, O,

where the ring or bicyclic ring system is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carbamoyl, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, (C₁-C₆-alkyl)carbonyl, (C₁-C₆-alkoxy)carbonyl, (C₁-C₆-alkyl)aminocarbonyl, di-(C₁-C₄-alkyl)aminocarbonyl,

-   Q_(Y) is a 5- or 6-membered, partly saturated or saturated     heterocyclic or heteroaromatic ring or an aromatic 8-, 9- or     10-membered fused heterobicyclic ring system, where the ring or ring     system is optionally mono- or polysubstituted, identically or     differently, and where the substituents may each independently be     selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl,     C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl,     C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carboxyl,     carbamoyl, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl,     C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl,     C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino,     C₃-C₆-cycloalkylamino, (C₁-C₆-alkyl)carbonyl,     (C₁-C₆-alkoxy)carbonyl, (C₁-C₆-alkyl)aminocarbonyl,     di-(C₁-C₄-alkyl)aminocarbonyl, tri-(C₁-C₂)alkylsilyl,     (C₁-C₄-alkyl)(C₁-C₄-alkoxy)imino,

or where the substituents may each independently be selected from phenyl or a 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,

-   R⁷ is hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl,     C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl,     C₃-C₆-cycloalkoxy or

-   R⁹ is independently hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl,     C₁-C₆-haloalkyl, halogen, cyano, nitro, C₁-C₄-alkoxy,     C₁-C₄-haloalkoxy, C₁-C₄-alkylthio or C₁-C₄-haloalkylthio, -   p is 0 to 4, -   Z is N, CH, CF, CCl, CBr or Cl,

the compounds of the general formula (I) also including N-oxides and salts (I),

and one or more further insecticides and/or acaricides from the group (II):

(1) Acetylcholinesterase (AChE) inhibitors, for example

carbamates, for example alanycarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimethacarb, XMC and xylylcarb; or organophosphates, for example acephate, azamethiphos, azinphos (-methyl, -ethyl), cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos (-methyl), coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos/DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, isofenphos, isopropyl O-(methoxyaminothiophosphoryl)salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, parathion (-methyl), phenthoate, phorate, phosalone, phosmet, phosphamidon, phoxim, pirimiphos (-methyl), profenofos, propetamphos, prothiofos, pyraclofos, pyridaphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, triclorfon and vamidothion.

(2) GABA-gated chloride channel antagonists, for example

organochlorines, for example chlordane and endosulfan (alpha-); or fiproles (phenylpyrazoles), for example ethiprole, fipronil, pyrafluprole and pyriprole.

(3) Sodium channel modulators/voltage-dependent sodium channel blockers, for example

pyrethroids, for example acrinathrin, allethrin (d-cis-trans, d-trans), bifenthrin, bioallethrin, bioallethrin-S-cyclopentenyl, bioresmethrin, cycloprothrin, cyfluthrin (beta-), cyhalothrin (gamma-, lambda-), cypermethrin (alpha-, beta-, theta-, zeta-), cyphenothrin [(1R)-trans-isomers], deltamethrin, dimefluthrin, empenthrin [(EZ)-(1R)-isomers], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, fluvalinate (tau-), halfenprox, imiprothrin, metofluthrin, permethrin, phenothrin [(1R)-trans-isomer], prallethrin, profluthrin, pyrethrins (pyrethrum), resmethrin, RU 15525, silafluofen, tefluthrin, tetramethrin [(1R)-isomers], tralomethrin, transfluthrin and ZXI 8901; or DDT; or methoxychlor.

(4) Nicotinergic acetylcholine receptor agonists, for example

neonicotinoids, for example acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam; or nicotine.

(5) Allosteric acetylcholine receptor modulators (agonists), for example

spinosyns, for example spinetoram and spinosad.

(6) chloride channel activators, for example

avermectins/milbemycins, for example abamectin, emamectin benzoate, lepimectin and milbemectin.

(7) Juvenile hormone analogues, for example hydroprene, kinoprene, methoprene; or fenoxycarb; pyriproxyfen.

(8) Active ingredients with unknown or nonspecific mechanisms of action, for example

fumigants, for example methyl bromide and other alkyl halides; or chloropicrin; sulphuryl fluoride; borax; tartar emetic.

(9) Selective antifeedants, for example pymetrozine; or flonicamid.

(10) mite growth inhibitors, for example clofentezine, diflovidazin, hexythiazox, etoxazole.

(11) microbial disruptors of the insect gut membrane, for example Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis, and BT plant proteins, for example Cry1Ab, Cry1Ac, Cry1Fa, Cry2Ab, mCry3A, Cry3Ab, Cry3Bb, Cry34/35Ab1.

(12) Oxidative phosphorylation inhibitors, ATP disruptors, for example diafenthiuron; or

organotin compounds, for example azocyclotin, cyhexatin, fenbutatin oxide; or propargite; tetradifon.

(13) Oxidative phosphorylation decouplers acting by interrupting the H proton gradient, for example chlorfenapyr and DNOC.

(14) Nicotinergic acetylcholine receptor antagonists, for example bensultap, cartap (hydrochloride), thiocylam, and thiosultap (sodium).

(15) Chitin biosynthesis inhibitors, type 0, for example benzoylureas, for example bistrifluron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron.

(16) Chitin biosynthesis inhibitors, type 1, for example buprofezin.

(17) Moulting disruptors, for example cyromazine.

(18) Ecdysone agonists/disruptors, for example diacylhydrazines, for example chromafenozide, halofenozide, methoxyfenozide and tebufenozide.

(19) Octopaminergic agonists, for example amitraz.

(20) Complex-III electron transport inhibitors, for example hydramethylnone; acequinocyl; fluacrypyrim.

(21) Complex-I electron transport inhibitors, for example from the group of the METI acaricides, for example fenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad, tolfenpyrad; or rotenone (Derris).

(22) Voltage-dependent sodium channel blockers, for example indoxacarb; metaflumizone.

(23) Inhibitors of acetyl-CoA carboxylase, for example tetronic acid derivatives, for example spirodiclofen and spiromesifen; or tetramic acid derivatives, for example spirotetramat.

(24) Complex-IV electron transport inhibitors, for example phosphines, for example aluminium phosphide, calcium phosphide, phosphine, zinc phosphide; or cyanide.

(25) Complex-II electron transport inhibitors, for example cyenopyrafen.

(28) Ryanodine receptor effectors, for example

diamides, for example chlorantraniliprole and flubendiamide. Further active ingredients with unknown mechanism of action, for example amidoflumet, azadirachtin, benclothiaz, benzoximate, bifenazate, bromopropylate, chinomethionat, cryolite, cyantraniliprole (Cyazypyr), cyflumetofen, dicofol, diflovidazin, fluensulfone, flufenerim, flufiprole, fluopyram, fufenozide, imidaclothiz, imicyafos, iprodione, pyridalyl, pyrifluquinazon and iodomethane; and also preparations based on Bacillus firmus (I-1582, BioNeem, Votivo), further compounds such as dichloropropene, oil (for example petroleum), metaldehyde, metam-sodium, and the following known active compounds:

3-bromo-N-{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl}-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide (known from WO2005/077934), 4-{[(6-bromopyrid-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-fluoropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(2-chloro-1,3-thiazol-5-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-chloropyrid-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one (known from WO2007/115644), 4-{[(6-chloro-5-fluoropyrid-3-yl)methyl](methyl)amino}furan-2(5H)-one (known from WO2007/115643), 4-{[(5,6-dichloropyrid-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one (known from WO2007/115646), 4-{[(6-chloro-5-fluoropyrid-3-yl)methyl](cyclopropyl)amino}furan-2(5H)-one (known from WO2007/115643), 4-{[(6-chloropyrid-3-yl)methyl](cyclopropyl)amino}furan-2(5H)-one (known from EP-A-0 539 588), 4-{[(6-chloropyrid-3-yl)methyl](methyl)amino}furan-2(5H)-one (known from EP-A-0 539 588), {[1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ⁴-sulphanylidene}) cyanamide (known from WO2007/149134) and its diastereomers {[(1R)-1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ⁴-sulphanylidene}cyanamide (A) and {[(1S)-1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ⁴-sulphanylidene}cyanamide (B) (likewise known from WO2007/149134) and sulfoxaflor (likewise known from WO2007/149134) and its diastereomers [(R)-methyl(oxido) {(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulphanylidene]cyanamide (A1) and [(S)-methyl(oxido) {(1S)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulphanylidene]cyanamide (A2), designated as diastereomer group A (known from WO 2010/074747, WO 2010/074751), [(R)-methyl(oxido){(1S)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulphanylidene]cyanamide (B1) and [(S)-methyl(oxido) ({(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulphanylidene]cyanamide (B2), designated as diastereomer group B (likewise known from WO 2010/074747, WO 2010/074751), and 11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1,4-dioxa-9-azadispiro[4.2.4.2]tetradec-11-en-10-one (known from WO2006/089633), 3-(4′-fluoro-2,4-dimethylbiphenyl-3-yl)-4-hydroxy-8-oxa-1-azaspiro[4.5]dec-3-en-2-one (known from WO2008/067911), 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulphinyl]phenyl}-3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine (known from WO2006/043635), [(3 S,4aR,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)oxy]-6,12-dihydroxy-4,12b-dimethyl-11-oxo-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-4-yl]methyl cyclopropanecarboxylate (known from WO2008/066153), 2-cyano-3-(difluoromethoxy)-N,N-dimethylbenzenesulphonamide (known from WO2006/056433), 2-cyano-3-(difluoromethoxy)-N-methylbenzenesulphonamide (known from WO2006/100288), 2-cyano-3-(difluoromethoxy)-N-ethylbenzenesulphonamide (known from WO2005/035486), 4-(difluoromethoxy)-N-ethyl-N-methyl-1,2-benzothiazol-3-amine 1,1-dioxide (known from WO2007/057407), N-[1-(2,3-dimethylphenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine (known from WO2008/104503), {1′-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indole-3,4′-piperidin]-1 (2H)-yl}(2-chloropyridin-4-yl)methanone (known from WO2003/106457), 3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4.5]dec-3-en-2-one (known from WO2009/049851), 3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-yl ethyl carbonate (known from WO2009/049851), 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from WO2004/099160), (2,2,3,3,4,4,5,5-octafluoropentyl)(3,3,3-trifluoropropyl)malononitrile (known from WO2005/063094), (2,2,3,3,4,4,5,5-octafluoropentyl)(3,3,4,4,4-pentafluorobutyl)malononitrile (known from WO2005/063094), 8-[2-(cyclopropylmethoxy)-4-(trifluoromethyl)phenoxy]-3-[6-(trifluoromethyl)pyridazin-3-yl]-3-azabicyclo[3.2.1]octane (known from WO2007/040280), 2-ethyl-7-methoxy-3-methyl-6-[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)oxy]quinolin-4-yl methyl carbonate (known from JP2008/110953), 2-ethyl-7-methoxy-3-methyl-6-[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)oxy]quinolin-4-yl acetate (known from JP2008/110953), PF1364 (CAS Reg. No. 1204776-60-2) (known from JP2010/018586), 5-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-(1H-1,2,4-triazol-1-yl)benzonitrile (known from WO2007/075459), 5-[5-(2-chloropyridin-4-yl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-(1H-1,2,4-triazol-1-yl)benzonitrile (known from WO2007/075459), 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}benzamide (known from WO2005/085216), 4-{[(6-chloropyridin-3-yl)methyl](cyclopropyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](ethyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](methyl)amino}-1,3-oxazol-2(5H)-one (all known from WO2010/005692), NNI-0711 (known from WO2002096882), 1-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-3-isobutylphenyl]-N-isobutyryl-3,5-dimethyl-1H-pyrazole-4-carboxamide (known from WO2002096882), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-chloro-3-methylbenzoyl]-2-methylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-ethylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-methylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-1,2-diethylhydrazinecarboxylate (known from WO2005/085216), methyl 2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-2-ethylhydrazinecarboxylate (known from WO2005/085216), (5RS,7RS;5RS,7SR)-1-(6-chloro-3-pyridylmethyl)-1,2,3,5,6,7-hexahydro-7-methyl-8-nitro-5-propoxyimidazo[1,2-a]pyridine (known from WO2007/101369), 2-{6-[2-(5-fluoropyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine (known from WO2010/006713), 2-{6-[2-(pyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine (known from WO2010/006713)

are very suitable for control of animal pests such as insects and/or acaricides. The active ingredients of group (II) are, in accordance with the IRAC classification, assigned to different classes and groups according to their mechanism of action.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

If, within this description, the short form of the common name of an active ingredient is used, this in each case encompasses all common derivatives, such as the esters and salts, and isomers, especially optical isomers, especially the commercial form or forms. If an ester or salt is referred to by the common name, this also refers in each case to all other common derivatives, such as other esters and salts, the free acids and neutral compounds, and isomers, especially optical isomers, especially the commercial form or forms. The chemical compound names mentioned refer to at least one of the compounds encompassed by the common name, frequently a preferred compound.

Surprisingly, the insecticidal and/or acaricidal action of the inventive active ingredient combinations is much higher than the total of the actions of the individual active ingredients. There is an unforeseeable true synergistic effect and not just complementary action.

Preferred combinations comprise at least one of the active ingredients of the formula (I) specified as preferred, more preferred, even more preferred or especially preferred and one or more active ingredients selected from the group (II).

Preferred, more preferred, even more preferred or especially preferred are active ingredients of the formula (I) where

-   R¹ is preferably hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl,     C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, cyano(C₁-C₆-alkyl),     C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl,     C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkyl,     C₁-C₄-alkylsulphinyl-C₁-C₄-alkyl or     C₁-C₄-alkylsulphonyl-C₁-C₄-alkyl, -   R¹ is more preferably hydrogen, methyl, ethyl, cyclopropyl,     cyanomethyl, methoxymethyl, methylthiomethyl, methylsulphinylmethyl     or methylsulphonylmethyl, -   R¹ is even more preferably hydrogen, -   R² is preferably hydrogen or C₁-C₆-alkyl. -   R² is more preferably hydrogen or methyl. -   R² is even more preferably hydrogen. -   R³ is preferably hydrogen or in each case optionally mono- or     polysubstituted identically or differently, C₁-C₄-alkyl,     C₁-C₄-alkoxy, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₃-C₆-cycloalkyl, where     the substituents may each independently be selected from halogen,     cyano, carboxyl, carbamoyl, nitro, hydroxyl, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl,     C₁-C₄-alkoxycarbonyl, C₁-C₄-alkylcarbonyl or a phenyl ring or a 4,     5- or 6-membered, aromatic partly saturated or saturated     heterocyclic ring, where the phenyl ring or heterocyclic ring is     optionally mono- or polysubstituted identically or differently, and     where the substituents may each independently be selected from     hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl,     C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl,     C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carboxyl,     carbamoyl, NO₂, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl,     C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl,     C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino,     C₃-C₆-cycloalkylamino, (C₁-C₆-alkyl)carbonyl, (C₁-C₆-alkoxy)carbonyl     or -   R³ is preferably C₂-C₄-alkoxycarbonyl, C₂-C₄-alkylcarbonyl,     C₂-C₄-alkylaminocarbonyl or C₂-C₄-dialkylaminocarbonyl, or -   R³ is preferably a phenyl ring, a 5- or 6-membered aromatic     heterocyclic ring or a 4-, 5- or 6-membered partly saturated or     saturated heterocyclic ring which may contain 1-3 heteroatoms from     the group of N, S, O, where the phenyl ring or heterocyclic ring is     optionally mono- or polysubstituted identically or differently, and     where the substituents may each independently be selected from     hydrogen, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl,     C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl, C₂-C₄-haloalkenyl,     C₂-C₄-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carboxyl,     carbamoyl, NO₂, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl,     C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl,     C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino,     C₃-C₆-cycloalkylamino, (C₁-C₄-alkyl)carbonyl,     (C₁-C₄-alkoxy)carbonyl, -   R³ is more preferably hydrogen or in each case optionally mono- or     polysubstituted identically or differently, C₁-C₄-alkyl, or     C₃-C₆-cycloalkyl, where the substituents may each independently be     selected from halogen, cyano, carboxyl, hydroxyl, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl,     C₂-C₄-alkoxycarbonyl, C₂-C₆-alkylcarbonyl or a phenyl ring or a 4-,     5- or 6-membered aromatic, partly saturated or saturated     heterocyclic ring, where the phenyl ring or heterocyclic ring is     optionally mono- or polysubstituted identically or differently, and     where the substituents may each independently be selected from     hydrogen, C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl,     C₂-C₄-haloalkenyl, C₂-C₄-haloalkynyl, C₃-C₆-halocycloalkyl, halogen,     cyano, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, or -   R³ is more preferably C₂-C₄-alkoxycarbonyl, C₂-C₄-alkylcarbonyl,     C₂-C₄-alkylaminocarbonyl, or -   R³ is more preferably a phenyl ring, a 5- or 6-membered aromatic     heterocyclic ring or a 4-, 5- or 6-membered partly saturated or     saturated heterocyclic ring which may contain 1-3 heteroatoms from     the group of N, S, O, where the phenyl ring or heterocyclic ring is     optionally mono- or polysubstituted identically or differently, and     where the substituents may each independently be selected from     hydrogen, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl,     C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl, C₂-C₄-haloalkenyl,     C₂-C₄-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carbamoyl,     NO₂, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, or -   R³ is even more preferably hydrogen, methyl, ethyl, n-propyl,     isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl,     cyclobutyl, azetidine, oxetane, thietane, pyrrolidine, pyrazolidine,     imidazolidine, imidazolidinone, tetrahydrofuran,     tetrahydrothiophene, tetrahydrothiophene dioxide, thiazoline,     thiazolidine, piperidine, piperazine, tetrahydropyran,     dihydrofuranone, dioxane, morpholine, thiomorpholine, thiomorpholine     dioxide, phenyl, pyridyl, or -   R³ is especially preferably hydrogen, methyl, isopropyl, cyclopropyl     or tert-butyl. -   R⁴ is preferably hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, halogen,     cyano, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio or     C₁-C₄-haloalkylthio,

two adjacent R⁴ radicals are likewise preferably —(CH₂)₃—, —(CH₂)₄—, —(CH₂)₅—, —(CH═CH—)₂—, —OCH₂O—, —O(CH₂)₂O—, —OCF₂O—, —(CF₂)₂O—, —O(CF₂)₂O—, —(CH═CH—CH═N)— or —(CH═CH—N═CH)—,

-   R⁴ is more preferably hydrogen, C₁-C₄-alkyl, C₁-C₂-haloalkyl,     halogen, cyano or C₁-C₂-haloalkoxy,

two adjacent R⁴ radicals are more preferably —(CH₂)₄—, —(CH═CH—)₂—, —O(CH₂)₂O—, —O(CF₂)₂O—, —(CH═CH—CH═N)— or —(CH═CH—N═CH)—,

-   R⁴ is even more preferably hydrogen, methyl, trifluoromethyl, cyano,     fluorine, chlorine, bromine, iodine or trifluoromethoxy. Even more     preferably, two adjacent R⁴ radicals are also —(CH₂)₄—, or     —(CH═CH—)₂—. -   R⁴ is especially preferably chlorine, fluorine or bromine, -   R⁴ is also especially preferably iodine or cyano,

two adjacent R⁴ radicals are especially preferably —(CH═CH—)₂

-   n is preferably 0, 1, 2, -   n is more preferably 1 or 2, -   n is even more preferably 1, -   R⁵ is preferably C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl,     C₁-C₆-halocycloalkyl, C₂-C₆-alkenyl, C₂-C₄-haloalkenyl,     C₂-C₄-alkynyl, C₂-C₄-haloalkynyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl,     C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl,     C₁-C₄-haloalkylsulphonyl, halogen, cyano, nitro or     C₃-C₆-trialkylsilyl, -   R⁵ is more preferably C₁-C₄-alkyl, C₃-C₆-cycloalkyl,     C₁-C₄-haloalkyl, C₁-C₆-halocycloalkyl, C₂-C₆-alkenyl,     C₂-C₄-haloalkenyl, C₂-C₄-alkynyl, C₂-C₄-haloalkynyl, C₁-C₄-alkoxy,     C₁-C₄-haloalkoxy, fluorine, chlorine, bromine, iodine, cyano, nitro     or C₃-C₆-trialkylsilyl, -   R⁵ is even more preferably methyl, fluorine, chlorine, bromine or     iodine, -   R⁵ is especially preferably methyl or chlorine, -   Q_(X) is preferably an optionally singly or multiply, identically or     differently R⁷-substituted 5-6 membered heteroaromatic ring which     may contain 1-3 heteroatoms from the group of N, O, S, or is phenyl, -   Q_(X) is more preferably an optionally singly or multiply,     identically or differently R⁷-substituted, 5- or 6-membered ring     selected from the group consisting of furan, thiophene, triazole,     imidazole, thiazole, oxazole, isoxazole, isothiazole, thiadiazole,     oxadiazole, pyrrole, pyridine, pyrimidine, pyridazine, pyrazine,     phenyl or pyrazole, -   Q_(X) is even more preferably thiazole, oxazole, pyrrole, imidazole,     triazole, pyrimidine, phenyl or pyrazole monosubstituted by the R⁷     group

where Z, R and p may have the general definitions specified above or the preferred or more preferred definitions specified below,

-   A is preferably optionally mono- or polysubstituted     —(C₁-C₄-alkylene)-, —(C₂-C₄-alkenylene)-, —(C₂-C₄-alkynylene)-,     —R⁸—(C₃-C₆-cycloalkyl)-R⁸—, —R⁸—O—R⁸—, —R⁸—S—R⁸—, —R⁸—S(═O)—R⁸—,     —R⁸—S(═O)₂—R⁸—, —R⁸—NH—(C₁-C₄-alkyl)-, —R⁸—N(C₁-C₄-alkyl)-R⁸,     —R⁸—C═NO(C₁-C₄-alkyl), —R⁸—C(═O)—R⁸, —R⁸—C(═S)—R⁸, —R⁸—C(═O)NH—R⁸,     R⁸—C(═O)N(C₁-C₄-alkyl)-R⁸, —R⁸—S(═O)₂NH—R⁸,     —R⁸—S(═O)₂N(C₁-C₄-alkyl)- R⁸, —R⁸—NH(C═O)O—R⁸,     —R⁸—N(C₁-C₄-alkyl)-(C═O)O—R⁸, —R⁸—NH(C═O)NH—R⁸, —R⁸—NHS(═O)₂—R⁸,     —R⁸—N(C₁-C₄-alkyl)S(═O)₂—R⁸, R⁸—NH—R⁸, R⁸—C(═O)—C(═O)—R⁸,     R⁸—C(OH)—R⁸, R⁸-Qz-R⁸,

where the substituents may each independently be selected from halogen, cyano, nitro, hydroxyl, C₁-C₆-alkyl, C₁-C₆-alkoxy or halogen-C₁-C₆-alkyl,

where Qz may have the general definitions specified above or the preferred or more preferred definitions specified below,

-   A is more preferably —CH₂—, —CH₂O—, —CH₂OCH₂—, —CH₂S—, —CH₂SCH₂—,     —CH₂N(C₁-C₄-alkyl)-, —CH₂N(C₁-C₄-alkyl)CH₂—, —CH(Hal)-, —C(Hal)₂-,     —CH(CN)—, CH₂(CO)—, CH₂(CS)—, CH₂CH(OH)—, -cyclopropyl-,     CH₂(CO)CH₂—, —CH(C₁-C₄-alkyl)-, —C(di-C₁-C₆-alkyl)-, —CH₂CH₂—,     —CH═CH—, —C≡C—, —C═NO(C₁-C₆-alkyl), —C(═O)(C₁-C₄-alkyl)-, -   A is even more preferably —CH₂—, —CH(CH₃), C(CH₃)₂, —CH₂CH₂—,     —CH(CN)—, —CH₂O— or —C(═O)—CH₂—, -   A is especially preferably CH₂, CH(CH₃), —CH₂O— or —C(═O)—CH₂—, -   Qz is preferably a 3- to 4-membered, partly saturated or saturated,     or a 5 to 6-membered, partly saturated, saturated or aromatic ring,     where the ring may optionally contain 1-3 heteroatoms from the group     of N, S, O,

where the ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl,

-   Qz is more preferably a 3- to 4-membered, partly saturated or     saturated, or a 5-membered, partly saturated, saturated or aromatic     ring, where the ring may optionally contain 1-2 heteroatoms from the     group of N, S, O,

where the ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl,

-   Qz is even more preferably azetidine, oxetane or thietane,     pyrrolidine, pyrroline, pyrazolidine, pyrazoline, imidazolidine,     imidazolidone, imidazoline, tetrahydrofuran, tetrahydrothiophene,     thiazolidine, isothiazolidine, isoxazoline,

which is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, methyl, ethyl, isopropyl, hydroxyl, methoxy, trifluoromethoxy, fluorine, chlorine, bromine, cyano, difluoromethyl, trifluoromethyl,

-   R⁷ is preferably C₁-C₆-alkyl or the radical

-   R⁷ is additionally preferably C₃-C₆-cycloalkoxy, -   R⁷ is more preferably methyl or the radical

-   R⁹ is independently preferably hydrogen, halogen, cyano,     C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkyl, C₁-C₄-haloalkoxy,     C₁-C₄-haloalkylsulphonyl or (C₁-C₄-alkyl)C₁-C₄-alkoxyimino, -   R⁹ is independently more preferably hydrogen, halogen, cyano or     C₁-C₄-haloalkyl, -   R⁹ is independently even more preferably fluorine, chlorine or     bromine, -   R⁹ is especially preferably chlorine, -   p is preferably 1, 2 or 3, -   p is more preferably 1 or 2, -   p is even more preferably 1, -   Z is preferably N, CH, CF, CCl, CBr or Cl, -   Z is more preferably N, CH, CF, CCl or CBr, -   Z is even more preferably N, CCl or CH, -   R⁸ is preferably linear or branched —(C₁-C₄-alkylene)- or a direct     bond -   R⁸ is more preferably methyl, ethyl, propyl, isopropyl, n-butyl,     sec-butyl or isobutyl or a direct bond -   R⁸ is even more preferably methyl or ethyl or a direct bond -   Q_(Y) is preferably a 5- or 6-membered, partly saturated or     saturated heterocyclic or heteroaromatic ring or an aromatic 8-, 9-     or 10-membered fused heterobicyclic ring system, where the     heteroatoms may be selected from the group of N, S, O, where the     ring or ring system is optionally mono- or polysubstituted     identically or differently, and where the substituents may each     independently be selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl,     C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl,     C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carboxyl,     carbamoyl, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,     C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl,     C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl,     C₁-C₄-haloalkylsulphonyl,

or where the substituents may each independently be selected from phenyl or a 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,

-   Q_(Y) is more preferably is an optionally mono- or polysubstituted     5- or 6-membered heteroaromatic ring from the group of Q-1 to Q-53     and Q-58 to Q-59, Q62 to Q63, an aromatic 9-membered fused     heterobicyclic ring system Q-54 to Q-56 and a 5-membered     heterocyclic ring Q-60 to Q-61, where the substituents may each     independently be selected from C₁-C₃-alkyl, C₁-C₃-haloalkyl,     C₁-C₂-alkoxy, halogen, cyano, hydroxyl, nitro or C₁-C₂-haloalkoxy,

or where the substituents may each independently be selected from phenyl or einem 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, NO₂, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,

-   Q_(Y) is even more preferably an optionally mono- or polysubstituted     5- or 6-membered heteroaromatic ring from the group of Q-36 to Q-40,     Q43, Q-58 to Q-59, Q62, Q63, an aromatic 9-membered fused     heterobicyclic ring system Q-54 to Q-56 and a 5-membered     heterocyclic ring Q-60 to Q-61, where the substituents may each     independently be selected from C₁-C₃-alkyl, C₁-C₃-haloalkyl,     C₁-C₂-alkoxy, halogen, cyano, hydroxyl, nitro or C₁-C₂-haloalkoxy,

or where the substituents may each independently be selected from phenyl or einem 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, nitro, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy,

-   Q_(Y) is especially preferably an optionally mono- or     polysubstituted identically or differently, heteroaromatic ring from     the group of Q-37, Q-38, Q-39, Q-40, Q43, Q-58, Q-59, Q62 and Q63,     and a 5-membered heterocyclic ring Q-60, where the substituents may     each independently be selected from methyl, ethyl, cyclopropyl,     tert-butyl, chlorine, fluorine, iodine, bromine, cyano, nitro,     difluoromethyl, trifluoromethyl, pentafluoroethyl,     heptafluoro-n-propyl and heptafluoroisopropyl

or where the substituents may each independently be selected from phenyl or a 5- or 6-membered heteroaromatic ring, where the substituents may each independently be selected from methyl, ethyl, cyclopropyl, tert-butyl, chlorine, fluorine, iodine, bromine, cyano, nitro, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoro-n-propyl and heptafluoroisopropyl,

The rings or ring systems shown above may optionally each independently be additionally substituted by oxo, thio, (═O)═NH, (═O)═N—CN, (═O)₂. Examples include tetrahydrothiophene dioxide, imidazolidone.

The oxo group as a substituent on a ring carbon atom is then, for example, a carbonyl group in the heterocyclic ring. As a result, lactones and lactams are preferably also included. The oxo group can also occur on the ring heteroatoms which can occur in different oxidation states, for example in the case of N and S, and then form, for example, the divalent groups —N(O)—, —S(O)— (or SO for short) and —S(O)₂— (or SO₂ for short) in the heterocyclic ring. In the case of —N(O)— and —S(O)— groups, both enantiomers are included in each case.

Substituents other than the oxo group may also be bonded to a heteroatom on a heterocyclic ring, for example to a nitrogen atom when a hydrogen atom on the nitrogen atom of the base skeleton is replaced. In the case of the nitrogen atom and also of other heteroatoms, for example of the sulphur atom, further substitution to form quarternary ammonium compounds or sulphonium compounds is also a possibility.

More particularly, the compounds of the formula (I) may be present in the form of different regioisomers: for example in the form of mixture of compounds with the definition of Q62 and Q63 or in the form of mixtures of Q58 and Q59. The invention therefore also encompasses active ingredient combinations comprising mixtures of compounds of the formula (I) where Q_(Y) is defined as Q62 and Q63, and Q58 and Q59, and the compounds may be present in different mixing ratios, and one or more active ingredients from group (II). Preference is given to mixing ratios of compounds of the formula (I) in which the Q_(Y) radical is Q62 or Q58 to compounds of the formula (I) in which the Qy radical is Q63 or Q59 of 60:40 to 99:1, more preferably of 70:30 to 97:3, even more preferably of 80:20 to 95:5. Especially preferred are the following mixing ratios of a compound of the formula (I) where Q_(Y) is defined as Q62 or Q58 to the compound of the formula (I) where Q_(Y) is defined as Q63 or Q59: 80:20; 81:19; 82:18; 83:17; 84:16; 85:15, 86:14; 87:13; 88:12; 89:11; 90:10, 91:9; 92:8; 93:7; 96:6; 95:5.

Additionally preferred are active ingredient combinations comprising at least one active ingredient of the formula (I-1)

in which

-   R³ is hydrogen or in each case optionally mono- or polysubstituted     identically or differently, C₁-C₆-alkyl, C₁-C₆-alkoxy,     C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₁₂-cycloalkyl,     C₃-C₁₂-cycloalkyl-C₁-C₆-alkyl, where the substituents may each     independently be selected from halogen, amino, cyano, nitro,     hydroxyl, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy,     C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₂-C₆-alkoxycarbonyl,     C₁-C₆-alkylcarbonyl C₃-C₆-cycloalkylamino or a 5- or 6-membered     heteroaromatic ring, -   R⁴ is halogen, cyano or methyl, -   R⁵ is methyl or chlorine, -   Z is N, CCl or CH, -   Qy an optionally mono- or polysubstituted 5- or 6-membered     heteroaromatic ring from the group of Q-36 to Q-40, Q43, Q-58 to     Q-59, Q62, Q63, an aromatic 9-membered fused heterobicyclic ring     system Q-54 to Q-56 and a 5-membered heterocyclic ring Q-60 to Q-61,     where the substituents may each independently be selected from     C₁-C₃-alkyl, C₁-C₃-haloalkyl, C₁-C₂-alkoxy, halogen, cyano,     hydroxyl, nitro or C₁-C₂-haloalkoxy,

where the compounds of the formula (I-1) may be present in the form of salts, and one or more active ingredients selected from group (II).

More preferred combinations are those comprising at least one of the active ingredients of the formula (I-1) specified as preferred, more preferred, even more preferred or especially preferred, and one or more active ingredients selected from group (II).

Preferred, more preferred, even more preferred or especially preferred active ingredients are those of the formula (I-1) where

-   R³ is preferably hydrogen or in each case optionally mono- or     polysubstituted identically or differently, C₁-C₆-alkyl,     C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl,     C₃-C₆-cycloalkyl-C₁-C₆-alkyl, where the substituents may each     independently be selected from halogen, cyano, amino, hydroxyl,     C₁-C₆-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio,     C₃-C₆-cycloalkyl, a 5- or 6-membered heteroaromatic ring containing     1-2 heteroatoms from the group of N, O, S, where no two oxygen atoms     in the ring are adjacent, -   R³ is more preferably one of the following radicals:

-   R⁴ is preferably halogen, cyano or methyl, -   R⁴ is more preferably chlorine and cyano, -   R⁴ is likewise more preferably bromine, fluorine, iodine or methyl, -   R⁵ is preferably and more preferably methyl, -   Z is preferably N or CH, Q_(Y) is preferably an optionally mono- or     polysubstituted identically or differently, heteroaromatic ring from     the group of Q-37, Q-38, Q-39, Q-40, Q43, Q-58, Q-59, Q62 and Q63,     and a 5-membered heterocyclic ring Q-60, where the substituents may     each independently be selected from methyl, ethyl, cyclopropyl,     tert-butyl, chlorine, fluorine, iodine, bromine, cyano, nitro,     difluoromethyl, trifluoromethyl, pentafluoroethyl,     heptafluoro-n-propyl and heptafluoroisopropyl. -   Q_(Y) is more preferably an optionally mono- or polysubstituted     identically or differently, heteroaromatic ring from the group of     Q-58 and Q-59, where the substituents may each independently be     selected from methyl, ethyl, cyclopropyl, tert-butyl,     difluoromethyl, trifluoromethyl, pentafluoroethyl,     n-heptafluoropropyl and isoheptafluoropropyl.

More particularly, the compounds of the formula (I-1) may be present in the form of different regioisomers, for example in the form of mixtures of compounds with the definition of Q62 and Q63 or in the form of mixtures of Q58 and Q59. The invention therefore also includes active ingredient combinations comprising mixtures of compounds of the formula (I-1) where Q_(Y) is defined as Q62 and Q63, and Q58 and Q59, and the compounds may be present in different mixing ratios, and one or more active ingredients from the group (II). Preference is given to mixing ratios of compounds of the formula (I) in which the Q_(Y) radical is Q62 or Q58 to compounds of the formula (I) in which the Qy radical is Q63 or Q59 of 60:40 to 99:1, more preferably of 70:30 to 97:3, even more preferably of 80:20 to 95:5. Especially preferred are the following mixing ratios of a compound of the formula (I) where Q_(Y) is defined as Q62 or Q58 to the compound of the formula (I) where Q_(Y) is defined as Q63 or Q59: 80:20; 81:19; 82:18; 83:17; 84:16; 85:15, 86:14; 87:13; 88:12; 89:11; 90:10, 91:9; 92:8; 93:7; 96:6; 95:5.

Additionally preferred are active ingredient combinations comprising at least one active ingredient of the general formula (I) or (I-1) and an active ingredient from group (II) selected from

-   acrinathrin -   alpha-cypermethrin -   betacyfluthrin -   cyhalothrin -   cypermethrin -   deltamethrin -   esfenvalerate -   etofenprox -   fenpropathrin -   fenvalerate -   flucythrinate -   lambda-cyhalothrin -   gamma-cyhalothrin -   permethrin -   tau-fluvalinate -   transfluthrin -   zeta-cypermethrin -   cyfluthrin -   bifenthrin -   tefluthrin -   eflusilanate -   fubfenprox -   pyrethrin -   resmethrin -   imidacloprid -   acetamiprid -   thiamethoxam -   nitenpyram -   thiacloprid -   dinotefuran -   clothianidin -   imidaclothiz -   chlorfluazuron -   diflubenzuron -   lufenuron -   teflubenzuron -   triflumuron -   novaluron -   flufenoxuron -   hexaflumuron -   bistrifluoron -   noviflumuron -   buprofezin -   cyromazine -   methoxyfenozide -   tebufenozide -   halofenozide -   chromafenozide -   endosulfan -   fipronil -   ethiprole -   pyrafluprole -   pyriprole -   flubendiamide -   chlorantraniliprole (Rynaxypyr) -   cyazypyr -   emamectin -   emamectin benzoate -   abamectin -   ivermectin -   milbemectin -   lepimectin -   tebufenpyrad -   fenpyroximate -   pyridaben -   fenazaquin -   pyrimidifen -   tolfenpyrad -   dicofol -   cyenopyrafen -   cyflumetofen -   acequinocyl -   fluacrypyrin -   bifenazate -   diafenthiuron -   etoxazole -   clofentezine -   spinosad -   triarathen -   tetradifon -   propargite -   hexythiazox -   bromopropylate -   chinomethionat -   amitraz -   pyrifluquinazone -   pymetrozine -   flonicamid -   pyriproxyfen -   diofenolan -   chlorfenapyr -   metaflumizone -   indoxacarb -   chlorpyrifos -   spirodiclofen -   spiromesifen -   spirotetramat -   pyridalyl -   spinetoram -   acephate -   triazophos -   profenofos -   fenamiphos -   4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoro-ethyl)amino}furan-2(5H)-one -   cadusaphos -   carbaryl -   carbofuran -   ethoprophos -   thiodicarb -   aldicarb -   metamidophos -   methiocarb -   sulfoxaflor

Additionally likewise preferred are active ingredient combinations comprising at least one active ingredient of the general formula (I) or (I-1) and an active ingredient of group (II) selected from

-   Bacillus firmus I-1582 -   dichloropropene -   dimethoate -   metaldehyde -   methomyl -   cartap -   oil (for example petroleum) -   chloropicrin -   carbosulfan -   dichlorvos -   metam-sodium -   phoxim -   monocrotophos -   oxamyl -   methidathion -   fenitrothion -   terbufos -   fluensulfone -   imicyafos -   11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1,4-dioxa-9-azadispiro[4.2.4.2]tetra     dec-11-en-10-one -   2-{6-[2-(5-fluoropyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine

Additionally more preferred are active ingredient combinations comprising at least one active ingredient of the general formula (I) or (I-1) and an active ingredient from group (II) selected from

-   acrinathrin -   alpha-cypermethrin -   betacyfluthrin -   cyhalothrin -   cypermethrin -   deltamethrin -   lambda-cyhalothrin -   gamma-cyhalothrin -   transfluthrin -   cyfluthrin -   bifenthrin -   tefluthrin -   imidacloprid -   acetamiprid -   thiamethoxam -   thiacloprid -   dinotefuran -   clothianidin -   lufenuron -   triflumuron -   novaluron -   flufenoxuron -   buprofezin -   methoxyfenozide -   tebufenozide -   fipronil -   ethiprole -   flubendiamide -   chlorantraniliprole (Rynaxypyr) -   cyazypyr -   emamectin -   emamectin benzoate -   abamectin -   milbemectin -   tebufenpyrad -   fenpyroximate -   diafenthiuron -   spinosad -   flonicamid -   chlorfenapyr -   metaflumizone -   indoxacarb -   chlorpyrifos -   spirodiclofen -   spiromesifen -   spirotetramat -   pyridalyl -   spinetoram -   acephate -   triazophos -   profenofos -   fenamiphos -   4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoro-ethyl)amino}furan-2(5H)-one -   cadusaphos -   carbaryl -   carbofuran -   ethoprophos -   thiodicarb -   aldicarb -   metamidophos -   methiocarb -   sulfoxaflor

Additionally likewise more preferred are active ingredient combinations comprising at least one active ingredient of the general formula (I) or (I-1) and an active ingredient from group (II) selected from

-   Bacillus firmus I-1582 -   dichloropropene -   dimethoate -   methomyl -   imicyafos -   fluensulfone -   11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1,4-dioxa-9-azadispiro[4.2.4.2]tetradec-11-en-10-one -   2-{6-[2-(5-fluoropyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine

Even more preferred active ingredient combinations comprise exactly one active ingredient of the formula (I-1-1) to (I-1-60) and one or more active ingredients from group (II).

Additionally even more preferred active ingredient combinations comprise the mixtures of active ingredients of the formula (I-1-1) to (I-1-60) and one or more active ingredients from group (II) specified hereinafter.

These mixtures are present preferably in a mixing ratio of 80:20 to 99:1. Mention should be made by way of example of the mixture I-1-1/I-1-7, the compound of the formula I-1-1 being present relative to the compound of the formula I-1-7 in a mixing ratio of 80:20 to 99:1. Mention should likewise be made by way of example of the mixture I-1-2/I-1-8, the compound of the formula I-1-2 being present relative to the compound of the formula I-1-8 in a mixing ratio of 80:20 to 99:1.

I-1-1-/1-1-7,

1-1-2/1-1-8, 1-1-3/1-1-9,

I-1-4/1-1-10, I-1-5/1-1-11, I-1-6/1-1-12, I-1-13/I-1-1-19,

1-1-14/1-1-20,

I-1-15/I-1-21, I-1-16/I-1-22, I-1-17/I-1-23, I-1-18/I-1-24,

1-1-25/1-1-31, 1-1-26/1-1-32,

I-1-27/I-1-33,

1-1-28/1-1-34,

I-1-29/I-1-35, I-1-30/I-1-36,

1-1-37/1-1-43, 1-1-38/1-1-44,

I-1-39/I-1-45, I-1-40/I-1-46, I-1-41/I-1-47, I-1-42/I-1-48, I-1-49/I-1-55, I-1-50/I-1-56, I-1-51/I-1-57, I-1-52/I-1-58, I-1-53/I-1-59, I-1-54/I-1-60.

Especially preferred are combinations comprising the active ingredient (I-1-1) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-2) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-3) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-4) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-5) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-6) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-7) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-8) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (1-1-9) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-10) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-11) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-12) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-13) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-14) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-15) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-16) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-17) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-18) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-19) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-20) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-21) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-22) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-23) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-24) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-25) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-26) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-27) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-28) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-29) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-30) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-31) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-32) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-33) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-34) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-35) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-36) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-37) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-38) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-39) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-40) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-41) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-42) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-43) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-44) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-45) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-46) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-47) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-48) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-49) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-50) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-51) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-52) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-53) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-54) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-55) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-56) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-57) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-58) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-59) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

Especially preferred are combinations comprising the active ingredient (I-1-60) and exactly one active ingredient from group II in the mixing ratios specified in Table 1.

The active ingredient combinations may additionally also comprise further fungicidally, acaricidally or insecticidally active mixture components.

When the active ingredients are present in particular weight ratios in the inventive active ingredient combinations, the improved effect is manifested. However, the weight ratios of the active ingredients in the active ingredient combinations can be varied within a relatively wide range. In general, the inventive combinations comprise active ingredients of the formula (I) to the mixing partner from group (II) in a ratio of 625:1 to 1:625; preferably in the preferred and more preferred mixing ratios specified in Table 1 below:

-   -   the mixing ratios are based on weight ratios. The ratio should         be understood as the active ingredient of the formula (I):mixing         partner to active ingredient of the formula (I):mixing partner.

Preferred More Most mixing preferred preferred Mixing partner ratio mixing ratio mixing ratio 1. acrinathrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 2. alpha-cypermethrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 3. betacyfluthrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 4. cyhalothrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 5. cypermethrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 6. deltamethrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 7. esfenvalerate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 8. etofenprox 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 9. fenpropathrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 10. fenvalerate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 11. flucythrinate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 12.a lambda-cyhalothrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 12.b gamma-cyhalothrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 13. permethrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 14. tau-fluvalinate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 15. transfluthrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 16. zeta-cypermethrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 17. cyfluthrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 18. bifenthrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 19. tefluthrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 20. eflusilanate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 21. fubfenprox 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 22. pyrethrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 23. resmethrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 24. imidacloprid 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 25. acetamiprid 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 26. thiamethoxam 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 27. nitenpyram 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 28. thiacloprid 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 29. dinotefuran 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 30. clothianidin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 31. imidaclothiz 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 32. chlorfluazuron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 33. diflubenzuron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 34. lufenuron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 35. teflubenzuron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 36. triflumuron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 37. novaluron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 38. flufenoxuron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 39. hexaflumuron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 40. bistrifluoron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 41. noviflumuron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 42. buprofezin 625:1 to 1:625 125:1 to 1:125 25:1 to 1:25 43. cyromazine 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 44. methoxyfenozide 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 45. tebufenozide 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 46. halofenozide 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 48. chromafenozide 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 49. endosulfan 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 50. fipronil 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 51. ethiprole 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 52. pyrafluprole 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 53. pyriprole 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 54. flubendiamide 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 55. chlorantraniliprole 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 (Rynaxypyr) 56. cyazypyr 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 57. emamectin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 58. emamectin benzoate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 59. abamectin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 60. ivermectin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 61. milbemectin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 62. lepimectin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 63. tebufenpyrad 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 64. fenpyroximate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 65. pyridaben 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 66. fenazaquin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 67. pyrimidifen 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 68. tolfenpyrad 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 69. dicofol 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 70. cyenopyrafen 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 71. cyflumetofen 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 72. acequinocyl 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 73. fluacrypyrin 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 74. bifenazate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 75. diafenthiuron 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 76. etoxazole 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 77. clofentezine 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 78. spinosad 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 79. triarathen 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 80. tetradifon 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 81. propargite 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 82. hexythiazox 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 83. bromopropylate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 84. chinomethionat 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 85. amitraz 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 86. pyrifluquinazone 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 87. pymetrozine 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 88. flonicamid 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 89. pyriproxyfen 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 90. diofenolan 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 91. chlorfenapyr 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 92. metaflumizone 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 93. indoxacarb 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 94. chlorpyrifos 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 95. spirodiclofen 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 96. spiromesifen 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 97. spirotetramat 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 98. pyridalyl 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 99. spinetoram 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 100. acephate 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 101. triazophos 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 102. profenofos 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 103. fenamiphos 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 104. 4-{[(6-chloropyrid- 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 3-yl)methyl](2,2- difluoro-ethyl) amino}-furan- 2(5H)-one 105. cadusaphos 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 106. carbaryl 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 107. carbofuran 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 108. ethoprophos 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 109. thiodicarb 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 110. aldicarb 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 111. metamidophos 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 112. methiocarb 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 113. sulfoxaflor 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 114. imicyafos 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 115. fluensulfone 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 116. Bacillus firmus 500:1 to 1:500 125:1 to 1:125 25:1 to 1:25 1-1582 117. 11-(4-chloro-2,6- 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 dimethylphenyl)- 12-hydroxy-1,4- dioxa-9-azadispiro [4.2.4.2]tetradec- 11-en-10-one 118. 2-{6-[2-(5- 125:1 to 1:125 25:1 to 1:25 5:1 to 1:5 fluoropyridin-3- yl)-1,3-thiazol-5- yl]pyridin-2- yl}pyrimidine

The inventive active ingredient combinations, given good plant tolerance, favourable homeotherm toxicity and good environmental compatibility, are suitable for protecting plants and plant organs, for increasing harvest yields, for improving the quality of the harvested material and for controlling animal pests, especially insects, arachnids, helminths, nematodes and molluscs, which are encountered in agriculture, in horticulture, in animal husbandry, in forests, in gardens and leisure facilities, in the protection of stored products and of materials, and in the hygiene sector. They can preferably be used as crop protection compositions. They are active against normally sensitive and resistant species and against all or some stages of development. The abovementioned pests include:

From the order of the Anoplura (Phthiraptera), for example, Damalinia spp., Haematopinus spp., Linognathus spp., Pediculus spp., Trichodectes spp.

From the class of the Arachnida, for example, Acarus spp., Aceria sheldoni, Aculops spp., Aculus spp., Amblyomma spp., Amphitetranychus viennensis, Argas spp., Boophilus spp., Brevipalpus spp., Bryobia praetiosa, Chorioptes spp., Dermanyssus gallinae, Eotetranychus spp., Epitrimerus pyri, Eutetranychus spp., Eriophyes spp., Halotydeus destructor, Hemitarsonemus spp., Hyalomma spp., Ixodes spp., Latrodectus mactans, Metatetranychus spp., Nuphersa spp., Oligonychus spp., Ornithodoros spp., Panonychus spp., Phyllocoptruta oleivora, Polyphagotarsonemus latus, Psoroptes spp., Rhipicephalus spp., Rhizoglyphus spp., Sarcoptes spp., Scorpio maurus, Stenotarsonemus spp., Tarsonemus spp., Tetranychus spp., Vasates lycopersici.

From the class of the Bivalva, for example, Dreissena spp.

From the order of the Chilopoda, for example, Geophilus spp., Scutigera spp.

From the order of the Coleoptera, for example, Acalymma vittatum, Acanthoscelides obtectus, Adoretus spp., Agelastica alni, Agriotes spp., Amphimallon solstitialis, Anobium punctatum, Anoplophora spp., Anthonomus spp., Anthrenus spp., Apion spp., Apogonia spp., Atomaria spp., Attagenus spp., Bruchidius obtectus, Bruchus spp., Cassida spp., Cerotoma trifurcata, Ceutorrhynchus spp., Chaetocnema spp., Cleonus mendicus, Conoderus spp., Cosmopolites spp., Costelytra zealandica, Ctenicera spp., Curculio spp., Cryptorhynchus lapathi, Cylindrocopturus spp., Dermestes spp., Diabrotica spp., Dichocrocis spp., Diloboderus spp., Epilachna spp., Epitrix spp., Faustinus spp., Gibbium psylloides, Hellula undalis, Heteronychus arator, Heteronyx spp., Hylamorpha elegans, Hylotrupes bajulus, Hypera postica, Hypothenemus spp., Lachnosterna consanguinea, Lema spp., Leptinotarsa decemlineata, Leucoptera spp., Lissorhoptrus oryzophilus, Lixus spp., Luperodes spp., Lyctus spp., Megascelis spp., Melanotus spp., Meligethes aeneus, Melolontha spp., Migdolus spp., Monochamus spp., Naupactus xanthographus, Niptus hololeucus, Oryctes rhinoceros, Oryzaephilus surinamensis, Oryzaphagus oryzae, Otiorrhynchus spp., Oxycetonia jucunda, Phaedon cochleariae, Phyllophaga spp., Phyllotreta spp., Popillia japonica, Premnotrypes spp., Psylliodes spp., Ptinus spp., Rhizobius ventralis, Rhizopertha dominica, Sitophilus spp., Sphenophorus spp., Sternechus spp., Symphyletes spp., Tanymecus spp., Tenebrio molitor, Tribolium spp., Trogoderma spp., Tychius spp., Xylotrechus spp., Zabrus spp.

From the order of the Collembola, for example, Onychiurus armatus.

From the order of the Diplopoda, for example, Blaniulus guttulatus.

From the order of the Diptera, for example, Aedes spp., Agromyza spp., Anastrepha spp., Anopheles spp., Asphondylia spp., Bactrocera spp., Bibio hortulanus, Calliphora erythrocephala, Ceratitis capitata, Chironomus spp., Chrysomyia spp., Cochliomyia spp., Contarinia spp., Cordylobia anthropophaga, Culex spp., Cuterebra spp., Dacus oleae, Dasyneura spp., Delia spp., Dermatobia hominis, Drosophila spp., Echinocnemus spp., Fannia spp., Gastrophilus spp., Hydrellia spp., Hylemyia spp., Hyppobosca spp., Hypoderma spp., Liriomyza spp. Lucilia spp., Musca spp., Nezara spp., Oestrus spp., Oscinella frit, Pegomyia spp., Phorbia spp., Prodiplosis spp., Psila rosae, Rhagoletis spp., Stomoxys spp., Tabanus spp., Tannia spp., Tetanops spp., Tipula spp.

From the class of the Gastropoda, for example, Arion spp., Biomphalaria spp., Bulinus spp., Deroceras spp., Galba spp., Lymnaea spp., Oncomelania spp., Pomacea spp., Succinea spp.

From the class of the helminths, for example, Ancylostoma duodenale, Ancylostoma ceylanicum, Acylostoma braziliensis, Ancylostoma spp., Ascaris lumbricoides, Ascaris spp., Brugia malayi, Brugia timori, Bunostomum spp., Chabertia spp., Clonorchis spp., Cooperia spp., Dicrocoelium spp, Dictyocaulus filaria, Diphyllobothrium latum, Dracunculus medinensis, Echinococcus granulosus, Echinococcus multilocularis, Enterobius vermicularis, Faciola spp., Haemonchus spp., Heterakis spp., Hymenolepis nana, Hyostrongulus spp., Loa Loa, Nematodirus spp., Oesophagostomum spp., Opisthorchis spp., Onchocerca volvulus, Ostertagia spp., Paragonimus spp., Schistosomen spp., Strongyloides fuelleborni, Strongyloides stercoralis, Stronyloides spp., Taenia saginata, Taenia solium, Trichinella spiralis, Trichinella nativa, Trichinella britovi, Trichinella nelsoni, Trichinella pseudopsiralis, Trichostrongulus spp., Trichuris trichiura, Wuchereria bancrofti.

It is also possible to control protozoa, such as Eimeria.

From the order of the Heteroptera, for example, Anasa tristis, Antestiopsis spp., Blissus spp., Calocoris spp., Campylomma livida, Cavelerius spp., Cimex spp., Collaria spp., Creontiades dilutus, Dasynus piperis, Dichelops furcatus, Diconocoris hewetti, Dysdercus spp., Euschistus spp., Eurygaster spp., Heliopeltis spp., Horcias nobilellus, Leptocorisa spp., Leptoglossus phyllopus, Lygus spp., Macropes excavatus, Miridae, Monalonion atratum, Nezara spp., Oebalus spp., Pentomidae, Piesma quadrata, Piezodorus spp., Psallus spp., Pseudacysta persea, Rhodnius spp., Sahlbergella singularis, Scaptocoris castanea, Scotinophora spp., Stephanitis nashi, Tibraca spp., Triatoma spp.

From the order of the Homoptera, for example, Acyrthosipon spp., Acrogonia spp., Aeneolamia spp., Agonoscena spp., Aleurodes spp., Aleurolobus barodensis, Aleurothrixus spp., Amrasca spp., Anuraphis cardui, Aonidiella spp., Aphanostigma piri, Aphis spp., Arboridia apicalis, Aspidiella spp., Aspidiotus spp., Atanus spp., Aulacorthum solani, Bemisia spp., Brachycaudus helichrysii, Brachycolus spp., Brevicoryne brassicae, Calligypona marginata, Carneocephala fulgida, Ceratovacuna lanigera, Cercopidae, Ceroplastes spp., Chaetosiphon fragaefolii, Chionaspis tegalensis, Chlorita onukii, Chromaphis juglandicola, Chrysomphalus ficus, Cicadulina mbila, Coccomytilus halli, Coccus spp., Cryptomyzus ribis, Dalbulus spp., Dialeurodes spp., Diaphorina spp., Diaspis spp., Drosicha spp., Dysaphis spp., Dysmicoccus spp., Empoasca spp., Eriosoma spp., Erythroneura spp., Euscelis bilobatus, Ferrisia spp., Geococcus coffeae, Hieroglyphus spp., Homalodisca coagulata, Hyalopterus arundinis, Icerya spp., Idiocerus spp., Idioscopus spp., Laodelphax striatellus, Lecanium spp., Lepidosaphes spp., Lipaphis erysimi, Macrosiphum spp., Mahanarva spp., Melanaphis sacchari, Metcalfiella spp., Metopolophium dirhodum, Monellia costalis, Monelliopsis pecanis, Myzus spp., Nasonovia ribisnigri, Nephotettix spp., Nilaparvata lugens, Oncometopia spp., Orthezia praelonga, Parabemisia myricae, Paratrioza spp., Parlatoria spp., Pemphigus spp., Peregrinus maidis, Phenacoccus spp., Phloeomyzus passerinii, Phorodon humuli, Phylloxera spp., Pinnaspis aspidistrae, Planococcus spp., Protopulvinaria pyriformis, Pseudaulacaspis pentagona, Pseudococcus spp., Psylla spp., Pteromalus spp., Pyrilla spp., Quadraspidiotus spp., Quesada gigas, Rastrococcus spp., Rhopalosiphum spp., Saissetia spp., Scaphoides titanus, Schizaphis graminum, Selenaspidus articulatus, Sogata spp., Sogatella furcifera, Sogatodes spp., Stictocephala festina, Tenalaphara malayensis, Tinocallis caryaefoliae, Tomaspis spp., Toxoptera spp., Trialeurodes spp., Trioza spp., Typhlocyba spp., Unaspis spp., Viteus vitifolii, Zygina spp.

From the order of the Hymenoptera, for example, Athalia spp., Diprion spp., Hoplocampa spp., Lasius spp., Monomorium pharaonis, Vespa spp.

From the order of the Isopoda, for example, Armadillidium vulgare, Oniscus asellus and Porcellio scaber.

From the order of the Isoptera, for example, Acromyrmex spp., Atta spp., Cornitermes cumulans, Microtermes obesi, Odontotermes spp., Reticulitermes spp.

From the order of the Lepidoptera, for example, Acronicta major, Adoxophyes spp., Aedia leucomelas, Agrotis spp., Alabama spp., Amyelois transitella, Anarsia spp., Anticarsia spp., Argyroploce spp., Barathra brassicae, Borbo cinnara, Bucculatrix thurberiella, Bupalus piniarius, Busseola spp., Cacoecia spp., Caloptilia theivora, Capua reticulana, Carpocapsa pomonella, Carposina niponensis, Cheimatobia brumata, Chilo spp., Choristoneura spp., Clysia ambiguella, Cnaphalocerus spp., Cnephasia spp., Conopomorpha spp., Conotrachelus spp., Copitarsia spp., Cydia spp., Dalaca noctuides, Diaphania spp., Diatraea saccharalis, Earias spp., Ecdytolopha aurantium, Elasmopalpus lignosellus, Eldana saccharina, Ephestia kuehniella, Epinotia spp., Epiphyas postvittana, Etiella spp., Eulia spp., Eupoecilia ambiguella, Euproctis spp., Euxoa spp., Feltia spp., Galleria mellonella, Gracillaria spp., Grapholitha spp., Hedylepta spp., Helicoverpa spp., Heliothis spp., Hofmannophila pseudospretella, Homoeosoma spp., Homona spp., Hyponomeuta padella, Kakivoria flavofasciata, Laphygma spp., Laspeyresia molesta, Leucinodes orbonalis, Leucoptera spp., Lithocolletis spp., Lithophane antennata, Lobesia spp., Loxagrotis albicosta, Lymantria spp., Lyonetia spp., Malacosoma neustria, Maruca testulalis, Mamestra brassicae, Mocis spp., Mythimna separata, Nymphula spp., Oiketicus spp., Oria spp., Orthaga spp., Ostrinia spp., Oulema oryzae, Panolis flammea, Parnara spp., Pectinophora spp., Perileucoptera spp., Phthorimaea spp., Phyllocnistis citrella, Phyllonorycter spp., Pieris spp., Platynota stultana, Plusia spp., Plutella xylostella, Prays spp., Prodenia spp., Protoparce spp., Pseudaletia spp., Pseudoplusia includens, Pyrausta nubilalis, Rachiplusia nu, Schoenobius spp., Scirpophaga spp., Scotia segetum, Sesamia spp., Sparganothis spp., Spodoptera spp., Stathmopoda spp., Stomopteryx subsecivella, Synanthedon spp., Tecia solanivora, Thermesia gemmatalis, Tinea pellionella, Tineola bisselliella, Tortrix spp., Trichoplusia spp., Tuta absoluta, Virachola spp.

From the order of the Orthoptera, for example, Acheta domesticus, Blatta orientalis, Blattella germanica, Dichroplus spp., Gryllotalpa spp., Leucophaea maderae, Locusta spp., Melanoplus spp., Periplaneta americana, Schistocerca gregaria.

From the order of the Siphonaptera, for example, Ceratophyllus spp., Xenopsylla cheopis.

From the order of the Symphyla, for example, Scutigerella spp.

From the order of the Thysanoptera, for example, Anaphothrips obscurus, Baliothrips biformis, Drepanothris reuteri, Enneothrips flavens, Frankliniella spp., Heliothrips spp., Hercinothrips femoralis, Rhipiphorothrips cruentatus, Scirtothrips spp., Taeniothrips cardamoni, Thrips spp.

From the order of the Thysanura, for example, Lepisma saccharina.

The phytoparasitic nematodes include, for example, Aphelenchoides spp., Bursaphelenchus spp., Ditylenchus spp., Globodera spp., Heterodera spp., Longidorus spp., Meloidogyne spp., Pratylenchus spp., Radopholus similis, Trichodorus spp., Tylenchulus semipenetrans, Xiphinema spp.

The active ingredient combinations can be converted to the customary formulations, such as solutions, emulsions, wettable powders, suspensions, powders, dusts, pastes, soluble powders, granules, suspoemulsion concentrates, natural products impregnated with active ingredient, synthetic substances impregnated with active ingredient, and also microencapsulations in polymeric substances.

These formulations are produced in a known manner, for example by mixing the active ingredients with extenders, i.e. liquid solvents, and/or solid carriers, optionally with the use of surfactants, i.e. emulsifiers and/or dispersants, and/or foam formers.

If the extender used is water, it is also possible to use, for example, organic solvents as auxiliary solvents. Useful liquid solvents essentially include: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics and chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example mineral oil fractions, mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulfoxide, and also water.

Useful solid carriers include:

for example ammonium salts and ground natural minerals, such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground synthetic minerals, such as finely divided silica, alumina and silicates; suitable solid carriers for granules are for example crushed and fractionated natural rocks, such as calcite, marble, pumice, sepiolite, dolomite and synthetic granules of inorganic and organic meals, and granules of organic material, such as sawdust, coconut shells, maize cobs and tobacco stalks; suitable emulsifiers and/or foam formers are for example nonionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates and protein hydrolysates; suitable dispersants are for example lignosulphite waste liquors and methylcellulose.

In the formulations it is possible to use tackifiers such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins and synthetic phospholipids. Further additives may be mineral and vegetable oils.

It is possible to use dyes such as inorganic pigments, for example iron oxide, titanium oxide and Prussian Blue, and organic dyes such as alizarin dyes, azo dyes and metal phthalocyanine dyes, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.

The formulations contain generally between 0.1 and 95% by weight of active ingredient, preferably between 0.5 and 90%.

The inventive active ingredient combinations may be present in commercially available formulations and in the use forms, prepared from these formulations, as a mixture with other active ingredients, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators or herbicides. The insecticides include, for example, phosphoric esters, carbamates, carboxylic esters, chlorinated hydrocarbons, phenylureas, substances produced by microorganisms, etc.

A mixture with other known active ingredients, such as herbicides, or with fertilizers and growth regulators, is also possible.

When used as insecticides, the inventive active ingredient combinations may also be present in their commercially available formulations and in the use forms, prepared from these formulations, as a mixture with synergists. Synergists are compounds which enhance the action of the active ingredients, without any need for the synergist added to be active itself.

The active ingredient content of the use forms prepared from the commercially available formulations may vary within wide limits. The active ingredient concentration of the application forms may be from 0.0000001 to 95% by weight of active ingredient, preferably between 0.0001 and 1% by weight.

The compounds are applied in a customary manner appropriate for the use forms.

All plants and plant parts can be treated in accordance with the invention. Plants are understood here to mean all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant varieties which are protectable and non-protectable by plant breeders' rights. Plant parts are understood to mean all parts and organs of plants above and below the ground, such as shoot, leaf, flower and root, examples of which include leaves, needles, stalks, stems, flowers, fruit bodies, fruits, seeds, roots, tubers and rhizomes. The plant parts also include harvested material and vegetative and generative propagation material, for example cuttings, tubers, rhizomes, slips and seeds.

The inventive treatment of the plants and plant parts with the active ingredient combinations is effected directly or by allowing them to act on the surroundings, habitat or storage space thereof by the customary treatment methods, for example by dipping, spraying, vaporizing, pouring on, nebulizing, scattering, painting on, and, in the case of propagation material, especially in the case of seeds, also by applying one or more coats.

As already mentioned above, it is possible to treat all plants and their parts in accordance with the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding methods, such as crossing or protoplast fusion, and also parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetical engineering, if appropriate in combination with conventional methods (Genetically Modified Organisms), and parts thereof are treated. The term “parts” or “parts of plants” or “plant parts” has been explained above.

More preferably, plants of the plant cultivars which are each commercially available or in use are treated in accordance with the invention.

Depending on the plant species or plant cultivars, and the location and growth conditions (soils, climate, vegetation period, diet) thereof, the inventive treatment may also result in superadditive (“synergistic”) effects. For example, possibilities include reduced application rates and/or broadening of the activity spectrum and/or an increase in the activity of the compounds and compositions usable in accordance with the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to levels of water or soil salinity, enhanced flowering performance, easier harvesting, accelerated ripening, higher yields, higher quality and/or higher nutritional value of the harvested products, increased storage life and/or processibility of the harvested products, which exceed the effects normally to be expected.

The transgenic plants or plant cultivars (those obtained by genetic engineering) which are to be treated with preference in accordance with the invention include all plants which, through the genetic modification, received genetic material which imparts particular advantageous useful properties (“traits”) to these plants. Examples of such properties are better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to levels of water or soil salinity, enhanced flowering performance, easier harvesting, accelerated ripening, higher yields, higher quality and/or a higher nutritional value of the harvested products, better storage life and/or processibility of the harvested products. Further and particularly emphasized examples of such properties are an improved defence of the plants against animal and microbial pests, such as against insects, mites, phytopathogenic fungi, bacteria and/or viruses, and also increased tolerance of the plants to certain herbicidally active ingredients. Examples of transgenic plants which may be mentioned are the important crop plants, such as cereals (wheat, rice), maize, soya beans, potatoes, cotton, oilseed rape and also fruit plants (with the fruits apples, pears, citrus fruits and grapes), and particular emphasis is given to maize, soya beans, potatoes, cotton and oilseed rape. Traits that are emphasized are in particular increased defense of the plants against insects by toxins formed in the plants, in particular those formed in the plants by the genetic material from Bacillus thuringiensis (for example by the genes CryIA(a), CryIA(b), CryIA(c), CryIIA, CryIIIA, CryIIIB2, Cry9c Cry2Ab, Cry3Bb and CryIF and also combinations thereof) (hereinbelow referred to as “Bt plants”). Traits that are additionally particularly emphasized are the increased tolerance of the plants to certain active herbicidal ingredients, for example imidazolinones, sulphonylureas, glyphosate or phosphinothricin (for example the “PAT” gene). The genes which impart the desired traits in question may also be present in combinations with one another in the transgenic plants. Examples of “Bt plants” include maize varieties, cotton varieties, soya varieties and potato varieties which are sold under the trade names YIELD GARD® (for example maize, cotton, soya), KnockOut® (for example maize), StarLink® (for example maize), Bollgard® (cotton), Nucotn® (cotton) and NewLeaf® (potato). Examples of herbicide-tolerant plants include maize varieties, cotton varieties and soya varieties which are sold under the trade names Roundup Ready® (tolerance to glyphosate, for example maize, cotton, soya), Liberty Link® (tolerance to phosphinothricin, for example oilseed rape), IMI® (tolerance to imidazolinones) and STS® (tolerance to sulphonylureas, for example maize). Herbicide-resistant plants (plants bred in a conventional manner for herbicide tolerance) also include the varieties sold under the Clearfield® name (for example maize). Of course, these statements also apply to plant cultivars which have these genetic traits or genetic traits which are still to be developed and will be developed and/or marketed in the future.

The plants listed can be treated according to the invention in a particularly advantageous manner with the active compound mixture according to the invention. The preferred ranges stated above for the mixtures also apply to the treatment of these plants. Particular emphasis is given to the treatment of plants with the mixtures specifically mentioned in the present text.

The good insecticidal and acaricidal action of the inventive active ingredient combinations is evident from the examples which follow. While the individual active ingredients have weaknesses in their action, the combinations exhibit an action which exceeds a simple sum of actions.

A synergistic effect in insecticides and acaricides is present whenever the action of the active ingredient combinations is greater than the sum of the actions of the active ingredients applied individually.

USE EXAMPLES

The expected action for a given combination of two active ingredients can be calculated according to S. R. Colby, Weeds 15 (1967), 20-22 as follows:

If

-   X is the kill rate, expressed in % of the untreated control, in the     case of use of active ingredient A in an application rate of m g/ha     or in a concentration of m ppm, -   Y is the kill rate, expressed in % of the untreated control, in the     case of use of active ingredient B in an application rate of n g/ha     or in a concentration of n ppm, and -   E is the kill rate, expressed in % of the untreated control, in the     case of use of active ingredients A and B in application rates of m     and n g/ha or in a concentration of m and n ppm,     then

$E = {X + Y - {\frac{X \cdot Y}{100}.}}$

If the actual kill rate is greater than that calculated, the kill rate of the combination is superadditive, which means that a synergistic effect is present. In this case, the kill rate actually observed must be greater than the value calculated from the above formula for the expected kill rate (E).

Example A Myzus persicae Test Solvent:

-   -   78 parts by weight of acetone     -   1.5 parts by weight of dimethylformamide         Emulsifier: 0.5 part by weight of alkylaryl polyglycol ether

To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.

Cabbage leaves (Brassica oleracea) severely infested by the green peach aphid (Myzus persicae) are treated by spraying with the active ingredient formulation in the desired concentration.

After the desired time, the kill in % is determined. 100% means that all aphids have been killed; 0% means that no aphids have been killed. The kill rates determined are entered into Colby's formula.

In this test, the following active ingredient combinations according to the present invention, for example, exhibited a synergistic enhancement in activity compared to the active ingredients applied individually:

TABLE A-1 Myzus persicae test Concentration Kill rate Active ingredient in g/ha in % after 1 d compound (I-1-2)/compound (I-1-8)*** 4 0 0.8 0 0.16 0 0.032 0 compound (I-1-1)/compound (I-1-7)*** 4 80 0.8 0 0.16 0 0.032 0 abamectin 0.16 0 compound (I-1-1)/compound (I-1-7)*** +  0.8 + 0.16 found* calc.** abamectin (5:1) 70 0 inventive acephate 100 0 compound (I-1-2)/compound (I-1-8)*** +  4 + 100 found* calc.** acephate (1:25) 80 0 inventive acrinathrin 0.8 0 compound (I-1-2)/compound (I-1-8)*** + 0.032 + 0.8  found* calc.** acrinathrin (1:25) 90 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.032 + 0.8  found* calc.** acrinathrin (1:25) 80 0 inventive alpha-cypermethrin 0.16 70 compound (I-1-2)/compound (I-1-8)*** + 0.16 + 0.16 found* calc.** alpha-cypermethrin (1:1) 90 70  inventive Bacillus firmus strain I-1582 250 0 compound (I-1-1)/compound (I-1-7)*** +  0.8 + 250  found* calc.** Bacillus firmus I-1582 (1:312.5) 100  80  inventive bifenthrin 0.8 80 compound (I-1-1)/compound (I-1-7)*** + 0.8 + 0.8 found* calc.** bifenthrin (1:1) 100  80  inventive β-cyfluthrin 0.16 70 0.032 0 compound (I-1-2)/compound (I-1-8)*** +  0.16 + 0.032 found* calc.** β-cyfluthrin (5:1) 70 0 inventive compound (I-1-1)/compound (I-1-7)*** +  0.8 + 0.16 found* calc.** β-cyfluthrin (5:1) 90 70  inventive buprofezin 500 0 compound (I-1-1)/compound (I-1-7)*** +  0.8 + 500  found* calc.** buprofezin (1:625) 70 0 inventive cadusaphos 20 0 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 20  found* calc.** cadusaphos (1:25) 90 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 20  found* calc.** cadusaphos (1:25) 90 0 inventive carbaryl 500 0 compound (I-1-2)/compound (I-1-8)*** +  4 + 500 found* calc.** carbaryl (1:125) 90 0 inventive carbofuran 20 70 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 20  found* calc.** carbofuran (1:25) 90 70  inventive chlorpyrifos 4 80 compound (I-1-2)/compound (I-1-8)*** + 0.16 + 4   found* calc.** chlorpyrifos (1:25) 100  80  inventive clothianidin 20 70 compound (I-1-2)/compound (I-1-8)*** +  4 + 20 found* calc.** clothianidin (1:5) 90 70  inventive cypermethrin 4 80 compound (I-1-1)/compound (I-1-7)*** + 0.8 + 4   found* calc.** cypermethrin (1:5) 100  80  inventive deltamethrin 0.8 0 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 0.8 found* calc.** deltamethrin (1:1) 100  0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 0.8 found* calc.** deltamethrin (1:1) 80 0 inventive diafenthiuron 100 0 compound (I-1-1)/compound (I-1-7)*** +  0.8 + 100  found* calc.** diafenthiuron (1:125) 70 0 inventive emamectin benzoate 0.8 0 0.16 0 compound (I-1-2)/compound (I-1-8)*** +   4 + 0.8 found* calc.** emamectin benzoate (5:1) 70 0 inventive compound (I-1-1)/compound (I-1-7)*** +  0.8 + 0.16 found* calc.** emamectin benzoate (5:1) 70 0 inventive ethiprole 4 0 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 4   found* calc.** ethiprole (1:5) 80 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 4   found* calc.** ethiprole (1:5) 70 0 inventive flonicamid 20 0 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 20  found* calc.** flonicamid (1:25) 80 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 20  found* calc.** flonicamid (1:25) 70 0 inventive gamma-cyhalothrin 0.032 0 compound (I-1-1)/compound (I-1-7)*** +  0.16 + 0.032 found* calc.** gamma-cyhalothrin (5:1) 70 0 inventive imidacloprid 0.8 0 compound (I-1-2)/compound (I-1-8)*** + 0.032 + 0.8  found* calc.** imidacloprid (1:25) 70 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.032 + 0.8  found* calc.** imidacloprid (1:25) 70 0 inventive indoxacarb 20 0 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 20  found* calc.** indoxacarb (1:25) 70 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 20  found* calc.** indoxacarb (1:25) 80 0 inventive L-cyhalothrin 0.16 0 compound (I-1-2)/compound (I-1-8)*** + 0.16 + 0.16 found* calc.** L-cyhalothrin (1:1) 80 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.16 + 0.16 found* calc.** L-cyhalothrin (1:1) 90 0 inventive metaflumizone 20 0 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 20 found* calc.** metaflumizone (1:25) 70 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 20  found* calc.** metaflumizone(1:25) 70 0 inventive methamidophos 100 80 20 0 compound (I-1-2)/compound (I-1-8)*** +  4 + 100 found* calc.** methamidophos (1:25) 100  80  inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 20  found* calc.** methamidophos (1:25) 90 0 inventive methiocarb 20 0 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 20  found* calc.** methiocarb (1:25) 70 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 20  found* calc.** methiocarb (1:25) 70 0 inventive milbemectin 0.8 0 compound (I-1-1)/compound (I-1-7)*** + 0.8 + 0.8 found* calc.** milbemectin (1:1) 70 0 inventive pyridalyl 4 0 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 4   found* calc.** pyridalyl (1:5) 70 0 inventive spinetoram 4 0 compound (I-1-2)/compound (I-1-8)*** + 4 + 4 found* calc.** spinetoram (1:1) 70 0 inventive spirodiclofen 100 0 20 0 compound (I-1-2)/compound (I-1-8)*** +  4 + 100 found* calc.** spirodiclofen (1:25) 70 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 20  found* calc.** spirodiclofen (1:25) 70 0 inventive spiromesifen 4 0 compound (I-1-1)/compound (I-1-7)*** + 0.8 + 4   found* calc.** spiromesifen (1:5) 70 0 inventive sulfoxaflor 0.16 0 compound (I-1-1)/compound (I-1-7)*** + 0.16 + 0.16 found* calc.** sulfoxaflor (1:1) 70 0 inventive tebufenpyrad 0.8 0 compound (I-1-1)/compound (I-1-7)*** + 0.8 + 0.8 found* calc.** tebufenpyrad (1:1) 70 0 inventive thiacloprid 20 80 compound (I-1-2)/compound (I-1-8)*** +  4 + 20 found* calc.** thiacloprid (1:5) 100  80  inventive thiamethoxam 20 70 compound (I-1-2)/compound (I-1-8)*** +  4 + 20 found* calc.** thiamethoxam (1:5) 100  70  inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 4   found* calc.** thiamethoxam (1:5) 90 70  inventive thiodicarb 20 0 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 20  found* calc.** thiodicarb (1:25) 70 0 inventive compound (I-1-1)/compound (I-1-7)*** + 0.8 + 20  found* calc.** thiodicarb (1:25) 70 0 inventive transfluthrin 20 70 compound (I-1-2)/compound (I-1-8)*** + 0.8 + 20  found* calc.** transfluthrin (1:25) 90 70  inventive triazophos 100 0 compound (I-1-2)/compound (I-1-8)*** +  0.8 + 100 found* calc.** triazophos (1:125) 70 0 inventive compound (I-1-1)/compound (I-1-7)*** +  0.8 + 100 found* calc.** triazophos (1:125) 70 0 inventive 4-{[(6-CHLOROPYRID-3- 20 0 YL)METHYL](2,2- DIFLUOROETHYL)AMINO}FURAN- 2(5H)-ONE compound (I-1-1)/compound (I-1-7)*** +   20 + 0.16 found* calc.** 4-{[(6-CHLOROPYRID-3- 70 0 YL)METHYL](2,2- DIFLUOROETHYL)AMINOIFURAN- 2(5H)-ONE (125:1) inventive pymetrozine 100 0 compound (I-1-1)/compound (I-1-7)*** +  4 + 100 found* calc.** pymetrozine (1:25) 100  0 inventive cyromazine 100 0 compound (I-1-1)/compound (I-1-7)*** +  4 + 100 found* calc.** cyromazine (1:25) 70 0 inventive

TABLE A-2 Myzus persicae test Concentration Kill rate Active ingredient in g/ha in % after 6^(d) compound (I-1-2)/compound 0.16  0 (I-1-8)*** 0.032  0 compound (I-1-1)/compound 0.16  70 (I-1-7)*** 0.032  0 acetamiprid 0.16  0 compound (I-1-1)/compound 0.032 + 0.16  found* calc.** (I-1-7)*** + acetamiprid (1: 5)  70  0 inventive aldicarb 0.8  0 compound (I-1-2)/compound 0.16 + 0.8  found* calc.** (I-1-8)*** + aldicarb (1: 5)  80  0 inventive chlorfenapyr 0.8  0 0.16  0 compound (I-1-2)/compound 0.16 + 0.8  found* calc.** (I-1-8)*** + chlorfenapyr (1: 5)  80  0 inventive compound (I-1-1)/compound 0.032 + 0.16  found* calc.** (I-1-7)*** + chlorfenapyr (1: 5)  70  0 inventive clothianidin 0.16  0 compound (I-1-1)/compound 0.032 + 0.16  found* calc.** (I-1-7)*** + clothianidin (1: 5)  70  0 inventive cyantraniliprole 0.16  0 compound (I-1-2)/compound 0.032 + 0.16  found* calc.** (I-1-8)*** + cyantraniliprole  80  0 (1: 5) inventive compound (I-1-1)/compound 0.032 + 0.16  found* calc.** (I-1-7)*** + cyantraniliprole  70  0 (1: 5) inventive diafenthiuron 20  70 compound (I-1-2)/compound 0.16 + 20   found* calc.** (I-1-8)*** + diafenthiuron 100 70 (1: 125) inventive ethoprophos 4  0 compound (I-1-2)/compound found* calc.** (I-1-8)*** + ethoprophos (1: 25) 0.16 + 4    80  0 inventive fenamiphos 0.8  0 compound (I-1-1)/compound 0.032 + 0.8  found* calc.** (I-1-7)*** + fenamiphos (1: 25)  70  0 inventive 11-(4-CHLORO-2,6- 0.8  0 DIMETHYLPHENYL)-12- HYDROXY-1,4-DIOXA-9- AZADISPIRO[4.2.4.2] TETRADEC-11-EN-10-ONE compound (I-1-1)/compound 0.032 + 0.8  found* calc.** (I-1-7)*** + 11-(4-CHLORO-  70  0 2,6-DIMETHYLPHENYL)-12- HYDROXY-1,4-DIOXA-9- AZADISPIRO[4.2.4.2] TETRADEC-11-EN-10-ONE (1: 25) inventive fipronil 0.16  0 compound (I-1-2)/compound 0.16 + 0.16 found* calc.** (I-1-8)*** + fipronil (1: 1)  80  0 inventive flufenoxuron 0.8  0 compound (I-1-1)/compound 0.032 + 0.8  found* calc.** (I-1-7)*** + flufenoxuron (1: 25)  70  0 inventive methoxyfenozide 4  0 compound (I-1-2)/compound 0.16 + 4   found* calc.** (I-1-8)*** + methoxyfenozide 100  0 (1: 25) inventive milbemectin 0.032  0 compound (I-1-1)/compound 0.032 + 0.032 found* calc.** (I-1-7)*** + milbemectin (1: 1)  70  0 inventive tebufenozide 4  0 compound (I-1-2)/compound 0.16 + 4   found* calc.** (I-1-8)*** + tebufenozide (1: 25) 100  0 inventive tebufenpyrad 0.16  0 compound (I-1-2)/compound 0.16 + 0.16 found* calc.** (I-1-8)*** + tebufenpyrad (1: 1)  80  0 inventive triflumuron 20  0 4  0 compound (I-1-2)/compound 0.16 + 20   found* calc.** (I-1-8)*** + triflumuron (1: 125)  90  0 inventive compound (I-1-1)/compound 0.032 + 4    found* calc.** (I-1-7)*** + triflumuron (1: 125)  70  0 inventive spinetoram 0.8  0 compound (I-1-1)/compound 0.16 + 0.8  found* calc.** (I-1-7)*** + spinetoram (1: 5)  90 70 inventive thiacloprid 0.8  80 compound (I-1-1)/compound 0.032 + 0.8  found* calc.** (I-1-7)*** + thiacloprid (1: 25) 100 80 inventive 2-{6-[2-(5-FLUOROPYRIDIN- 0.8  70 3-YL)-1,3-THIAZOL-5- YL]PYRIDIN-2-YL} PYRIMIDINE compound (I-1-1)/compound 0.032 + 0.8  found* calc.** (I-1-7)*** + 2-{6-[2-(5- 100 70 FLUOROPYRIDIN-3-YL)-1,3- THIAZOL-5-YL]PYRIDIN-2- YL}PYRIMIDINE (1: 25) inventive *found = effect found **calc. = effect calculated by Colby's formula ***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.

Example B Phaedon cochleariae Larvae Test Solvent:

-   -   78 parts by weight of acetone     -   1.5 parts by weight of dimethylformamide         Emulsifier: 0.5 part by weight of alkylaryl polyglycol ether

To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.

Cabbage leaves (Brassica oleracea) are treated by spraying with the active ingredient formulation of the desired concentration and populated with larvae of the mustard beetle (Phaedon cochleariae) while the leaves are still moist.

After the desired period of time, the kill rate in % is determined. 100% means that all beetle larvae have been killed; 0% means that none of the beetle larvae have been killed. The kill rates determined are entered into Colby's formula.

In this test, the following active ingredient combinations according to the present application exhibit a synergistic enhancement in activity compared to the active ingredients applied individually:

TABLE B-1 Phaedon cochleariae larvae test Concentration Kill rate Active ingredient in g/ha in % after 2^(d) compound (I-1-2)/compound 0.16  50 (I-1-8)*** 0.032  0 compound (I-1-1)/compound 0.16  67 (I-1-7)*** aldicarb 0.8  0 compound (I-1-1)/compound 0.16 + 0.8  found* calc.** (I-1-7)*** + aldicarb (1: 5) 100 67 inventive β-cyfluthrin 0.032  0 compound (I-1-2)/compound  0.16 + 0.032 found* calc.** (I-1-8)*** + β-cyfluthrin (5: 1)  67 50 inventive cyantraniliprole 0.16  0 compound (I-1-2)/compound 0.032 + 0.16  found* calc.** (I-1-8)*** + cyantraniliprole  33  0 (1: 5) inventive dinotefuran 20  0 compound (I-1-2)/compound 0.16 + 20   found* calc.** (I-1-8)*** + dinotefuran  83 50 (1: 125) inventive compound (I-1-1)/compound 0.16 + 20   found* calc.** (I-1-7)*** + dinotefuran (1: 125) 100 67 inventive fipronil 0.16  67 compound (I-1-2)/compound 0.16 + 0.16 found* calc.** (I-1-8)*** + fipronil (1: 1) 100 83.5 inventive compound (I-1-1)/compound 0.16 + 0.16 found* calc.** (I-1-7)*** + fipronil (1: 1) 100 83.5 inventive profenophos 4  0 compound (I-1-2)/compound 0.16 + 4   found* calc.** (I-1-8)*** + profenophos (1: 25)  83 50 inventive tebufenozide 4  0 compound (I-1-2)/compound 0.16 + 4   found* calc.** (I-1-8)*** + tebufenozide (1: 1)  83 50 inventive *found = effect found **calc. = effect calculated by Colby's formula ***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.

TABLE B-2 Phaedon cochleariae larvae test Concentration Kill rate Active ingredient in g/ha in % after 6^(d) compound (I-1-2)/compound 0.032  0 (I-1-8)*** compound (I-1-1)/compound 0.16  83 (I-1- 7)*** 0.032  0 abamectin 0.032  0 compound (I-1-1)/compound  0.16 + 0.032 found* calc.** (I-1-7)*** + abamectin (5: 1) 100 83 inventive acephate 4  0 compound (I-1-1)/compound 0.16 + 4   found* calc.** (I-1-7)*** + acephate (1: 25) 100 83 inventive cyantraniliprole 0.16  0 compound (I-1-2)/compound 0.032 + 0.16  found* calc.** (I-1-8)*** + cyantraniliprole (1: 5)  50  0 inventive compound (I-1-1)/compound 0.032 + 0.16  found* calc.** (I-1-7)*** + cyantraniliprole (1: 5) 100  0 inventive cypermethrin 0.16  0 compound (I-1-2)/compound 0.032 + 0.16  found* calc.** (I-1-8)*** + cypermethrin (1: 5)  33  0 inventive emamectin benzoate 0.032  0 compound (I-1-1)/compound  0.16 + 0.032 found* calc.** (I-1-7)*** + emamectin benzoate 100 83 (5: 1) inventive ethoprophos 0.8  0 compound (I-1-2)/compound 0.032 + 0.8  found* calc.** (I-1-8)*** + ethoprophos (1: 25)  33  0 inventive flubendiamide 0.8  0 compound (I-1-1)/compound 0.16 + 0.8  found* calc.** (I-1-7)*** + flubendiamide (1: 5) 100 83 inventive novaluron 0.8  0 compound (I-1-1)/compound 0.16 + 0.8  found* calc.** (I-1-7)*** + novaluron (1: 5) 100 83 inventive profenophos 4  0 compound (I-1-1)/compound 0.16 + 4   found* calc.** (I-1-7)*** + profenophos (1: 25) 100 83 inventive spirodiclofen 4  0 compound (I-1-1)/compound 0.16 + 4   found* calc.** (I-1-7)*** + spirodiclofen (1: 25) 100 83 inventive tebufenpyrad 0.16  0 compound (I-1-1)/compound 0.16 + 0.16 found* calc.** (I-1-7)*** + tebufenpyrad (1: 1) 100 83 inventive triflumuron 4  0 compound (I-1-2)/compound 0.032 + 4    found* calc.** (I-1-8)*** + triflumuron (1: 125)  50  0 inventive spinetoram 0.16  0 compound (I-1-1)/compound 0.032 + 0.16  found* calc.** (I-1-7)*** + spinetoram (1: 5)  33  0 inventive pyridalyl 4  0 compound (I-1-1)/compound 0.16 + 4   found* calc.** (I-1-7)*** + pyridalyl (1: 25) 100 83 inventive methoxyfenozide 0.8  0 compound (I-1-1)/compound 0.16 + 0.8  found* calc.** (I-1-7)*** + methoxyfenozide 100 83 (1: 5) inventive 2-{6-[2-(5-FLUOROPYRIDIN-3- 0.16  0 YL)-1,3-THIAZOL-5- YL]PYRIDIN-2- YL}PYRIMIDINE compound (I-1-1)/compound 0.16 + 4   found* calc.** (I-1-7)*** + 2-{6-[2-(5- 100 83 FLUOROPYRIDIN-3-YL)-1,3- THIAZOL-5-YL]PYRIDIN-2- YL}PYRIMIDINE (1: 25) inventive cyromazine 4  0 compound (I-1-1)/compound 0.16 + 4   found* calc.** (I-1-7)*** + cyromazine (1: 25) 100 83 inventive cyflumetofen 4  0 compound (I-1-1)/compound 0.16 + 4   found* calc.** (I-1-7)*** + Cyflumetofen (1: 25) 100 83 inventive *found = effect found **calc. = effect calculated by Colby's formula ***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.

Example C Spodoptera frugiperda Larvae Test Solvent:

-   -   78 parts by weight of acetone     -   1.5 parts by weight of dimethylformamide         Emulsifier: 0.5 part by weight of alkylaryl polyglycol ether

To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.

Cabbage leaves (Brassica oleracea) are treated by spraying with the active ingredient formulation of the desired concentration and populated with larvae of the army worm (Spodopter frugiperda) while the leaves are still moist.

After the desired time, the kill in % is determined. 100% means that all caterpillars have been killed; 0% means that none of the caterpillars have been killed. The kill rates determined are entered into Colby's formula.

In this test, the following active ingredient combinations according to the present application exhibit a synergistic enhancement in activity compared to the active ingredients applied individually:

TABLE C-1 Spodoptera frugiperda larvae test Concentration Kill rate Active ingredient in g/ha in % after 2^(d) compound (I-1-2)/compound 0.16 33 (I-1-8)*** 0.032 17 fenpyroximate 0.8  0 compound (I-1-2)/compound 0.16 + 0.8  found* calc.** (I-1-8)*** + fenpyroximate 83 33 (1: 5) inventive gamma-cyhalothrin 0.032 17 compound (I-1-2)/compound  0.16 + 0.032 found* calc.** (I-1-8)*** + fenpyroximate 83 44.39 (5: 1) inventive indoxacarb 0.8 50 compound (I-1-2)/compound 0.032 + 0.8  found* calc.** (I-1-8)*** + indoxacarb (1: 25) 83 58.5 inventive triazophos 4  0 compound (I-1-2)/compound 0.032 + 4    found* calc.** (I-1-8)*** + triazophos (1: 125) 67 17 inventive *found = effect found **calc. = effect calculated by Colby's formula ***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.

TABLE C-2 Concentration Kill rate Active ingredient in g/ha in % after 6^(d) compound (I-1-1)/compound 0.16  33 (I-1-7)*** 0.032  0 carbaryl 4  0 compound (I-1-1)/compound 0.032 + 4 found* calc.** (I-1-7)*** + carbaryl (1: 125)  50  0 inventive fluensulfone 2000  0 compound (I-1-1)/compound 0.16 + 2000 found* calc.** (I-1-7)*** + fluensulfone  67 33 (1: 12500) inventive flufenoxuron 0.8  0 compound (I-1-1)/compound 0.032 + 0.8 found* calc.** (I-1-7)*** + flufenoxuron 100  0 (1: 25) inventive imicyafos 45  0 compound (I-1-1)/compound 0.16 + 45 found* calc.** (I-1-7)*** + imicyafos  83 33 (1: 281.25) inventive L-cyhalothrin 0.032  0 compound (I-1-1)/compound 0.032 + 0.032 found* calc.** (I-1-7)*** + L-cyhalothrin (1: 1)  83  0 inventive lufenuron 0.8  17 compound (I-1-1)/compound 0.032 + 0.8 found* calc.** (I-1-7)*** + lufenuron (1: 25)  67 17 inventive novaluron 0.8  67 compound (I-1-1)/compound 0.032 + 0.8 found* calc.** (I-1-7)*** + novaluron (1: 25)  83 67 inventive profenophos 4  17 compound (I-1-1)/compound 0.032 + 4 found* calc.** (I-1-7)*** + profenophos  67 17 (1: 125) inventive chloranthraniliprole 0.032  50 compound (I-1-1)/compound 0.032 + 0.032 found* calc.** (I-1-7)*** + chloranthraniliprole 100 50 (1: 1) inventive spinosad 0.16  0 compound (I-1-1)/compound 0.032 + 0.16 found* calc.** (I-1-7)*** + spinosad (1: 5)  33  0 inventive tebufenozide 0.16  0 compound (I-1-1)/compound 0.032 + 0.16 found* calc.** (I-1-7)*** + tebufenozide (1: 5)  33  0 inventive pyridalyl 4  0 compound (I-1-1)/compound 0.16 + 4 found* calc.** (I-1-7)*** + pyridalyl (1: 25)  50 33 inventive methoxyfenozide 0.8  0 compound (I-1-1)/compound 0.16 + 0.8 found* calc.** (I-1-7)*** + methoxyfenozide  67 33 (1: 5) inventive cyromazine 4  0 compound (I-1-1)/compound 0.16 + 4 found* calc.** (I-1-7)*** + cyromazine (1: 25)  50 33 inventive cyflumetofen 4  17 compound (I-1-1)/compound 0.16 + 4 found* calc.** (I-1-7)*** + cyflumetofen  50 33 (1: 25) inventive *found = effect found **calc. = effect calculated by Colby's formula ***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.

Example D Tetranychus Test (OP-Resistant/Spray Treatment) Solvent:

-   -   78 parts by weight of acetone     -   1.5 parts by weight of dimethylformamide         Emulsifier: 0.5 part by weight of alkylaryl polyglycol ether

To produce an appropriate active ingredient formulation, 1 part by weight of active ingredient is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.

Discs of bean leaves (Phaseolus vulgaris) infested by all stages of the two-spotted spider mite (Tetranychus urticae) are sprayed with an active ingredient formulation of the desired concentration.

After the desired period of time, the effect in % is determined. 100% means that all of the spider mites have been killed; 0% means that none of the spider mites have been killed.

In this test, the following active ingredient combination according to the present application exhibited a synergistic enhancement in activity compared to the active ingredients applied individually:

TABLE D-1 Tetranychus urticae test Concentration Kill rate Active ingredient in g/ha in % after 2^(d) compound (I-1-2)/compound 4  0 (I-1-8)*** 0.8  0 0.16  0 0.032  0 compound (I-1-1)/compound 4  0 (I-1-7)*** 0.8  0 0.16  0 0.032  0 acrinathrin 4 20 0.8  0 compound (I-1-2)/compound 0.16 + 4   found* calc.** (I-1-8)*** + acrinathrin (1: 25) 70 20 inventive alpha-cypermethrin 4  0 compound (I-1-2)/compound 4 + 4 found* calc.** (I-1-8)*** + alpha-cypermethrin 80  0 (1: 1) inventive compound (I-1-1)/compound 4 + 4 found* calc.** (I-1-7)*** + alpha-cypermethrin 70  0 (1: 1) inventive bifenthrin 0.16  0 compound (I-1-2)/compound 0.16 + 0.16 found* calc.** (I-1-8)*** + bifenthrin (1: 1) 70  0 inventive compound (I-1-1)/compound 0.16 + 0.16 found* calc.** (I-1-7)*** + bifenthrin (1: 1) 40  0 inventive carbaryl 500 10 compound (I-1-2)/compound  4 + 500 found* calc.** (I-1-8)*** + carbaryl (1: 125) 50 10 inventive chlorfenapyr 4 10 compound (I-1-2)/compound 0.8 + 4   found* calc.** (I-1-8)*** + chlorfenapyr (1: 5) 70 10 inventive compound (I-1-1)/compound 0.8 + 4   found* calc.** (I-1-7)*** + chlorfenapyr (1: 5) 80 10 inventive diafenthiuron 100  0 compound (I-1-2)/compound   0.8 + 100 found* calc.** (I-1-8)*** + diafenthiuron (1: 125) 70  0 inventive emamectin benzoate 0.032  0 compound (I-1-2)/compound  0.16 + 0.032 found* calc.** (I-1-8)*** + emamectin benzoate 30  0 (5: 1) inventive fenamiphos 20  0 compound (I-1-2)/compound 0.8 + 20  found* calc.** (I-1-8)*** + fenamiphos (1: 25) 20  0 inventive fenpyroximate 0.8  0 compound (I-1-2)/compound 0.032 + 0.8  found* calc.** (I-1-8)*** + fenpyroximate (1: 25) 50  0 inventive compound (I-1-1)/compound 0.032 + 0.8  found* calc.** (I-1-7)*** + fenpyroximate (1: 25) 80  0 inventive flubendiamide 20  0 compound (I-1-1)/compound  4 + 20 found* calc.** (I-1-7)*** + flubendiamide (1: 5) 30  0 inventive fluensulfone 2000  0 compound (I-1-1)/compound   4 + 2000 found* calc.** (I-1-7)*** + fluensulfone (1: 500) 30  0 inventive gamma-cyhalothrin 0.8  0 compound (I-1-1)/compound 0.8 + 0.8 found* calc.** (I-1-7)*** + gamma-cyhalothrin 30  0 (1: 1) inventive lufenuron 100  0 compound (I-1-1)/compound  4 + 100 found* calc.** (I-1-7)*** + lufenuron (1: 25) 20  0 inventive milbemectin 0.032 50 compound (I-1-1)/compound 0.032 + 0.032 found* calc.** (I-1-7)*** + milbemectin (1: 1) 80  0 inventive spinosad 20 20 compound (I-1-2)/compound  4 + 20 found* calc.** (I-1-8)*** + spinosad (1: 5) 60 20 inventive spirodiclofen 100  0 compound (I-1-2)/compound  4 + 100 found* calc.** (I-1-8)*** + spirodiclofen (1: 25) 70  0 inventive compound (I-1-1)/compound  4 + 100 found* calc.** (I-1-7)*** + spirodiclofen (1: 25) 80  0 inventive spirotetramat 4  0 compound (I-1-2)/compound 0.8 + 4   found* calc.** (I-1-8)*** + spirotetramat (1: 5) 20  0 inventive tebufenpyrad 0.16  0 compound (I-1-1)/compound 0.032 + 0.16  found* calc.** (I-1-7)*** + tebufenpyrad (1: 5) 40  0 inventive thiodicarb 100  0 compound (I-1-2)/compound  4 + 100 found* calc.** (I-1-8)*** + thiodicarb (1: 25) 50  0 inventive compound (I-1-1)/compound  4 + 100 found* calc.** (I-1-7)*** + thiodicarb (1: 25) 70  0 inventive 4-{[(6-CHLOROPYRID-3-YL) 20  0 METHYL](2,2-DIFLUOROETHYL) AMINO}FURAN-2(5H)-ONE compound (I-1-1)/compound  4 + 20 found* calc.** (I-1-7)*** + 4-{[(6-CHLOROPYRID- 20  0 3-YL)METHYL](2,2- DIFLUOROETHYL)AMINO} FURAN-2(5H)-ONE (1: 5) inventive *found = effect found **calc. = effect calculated by Colby's formula ***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%.

TABLE D-2 Concentration Kill rate Active ingredient in g/ha in % after 6^(d) compound (I-1-2)/compound 4  0 (I-1-8)*** 0.8  0 0.16  0 0.032  0 compound (I-1-1)/compound 4  10 (I-1-7)*** 0.8  10 0.16  0 0.032  0 acrinathrin 0.8  40 compound (I-1-2)/compound 0.032 + 0.8  found* calc.** (I-1-8)*** + acrinathrin (1: 25)  70 40 inventive compound (I-1-1)/compound 0.032 + 0.8  found* calc.** (I-1-7)*** + acrinathrin (1: 25)  80 40 inventive abamectin 0.032  80 0.0064  0 compound (I-1-2)/compound  0.16 + 0.032 found* calc.** (I-1-8)*** + abamectin (5: 1) 100 80 inventive compound (I-1-1)/compound  0.032 + 0.0064 found* calc.** (I-1-7)*** + abamectin (5: 1)  70  0 inventive cadusaphos 20  0 compound (I-1-2)/compound 0.8 + 20  found* calc.** (I-1-8)*** + cadusaphos (1: 25)  40  0 inventive carbaryl 500  20 compound (I-1-2)/compound  4 + 500 found* calc.** (I-1-8)*** + carbaryl (1: 125)  70 20 inventive chlorpyrifos 100  0 compound (I-1-2)/compound  4 + 100 found* calc.** (I-1-8)*** + chlorpyrifos (1: 25)  30  0 inventive compound (I-1-1)/compound  4 + 100 found* calc.** (I-1-7)*** + chlorpyrifos (1: 25)  70 10 inventive diafenthiuron 20  10 compound (I-1-2)/compound 0.16 + 20   found* calc.** (I-1-8)*** + diafenthiuron  30 10 (1: 125) inventive L-cyhalothrin 4  20 compound (I-1-1)/compound 4 + 4 found* calc.** (I-1-7)*** + L-cyhalothrin (1: 1)  70 28 inventive spinetoram 4  20 compound (I-1-2)/compound 4 + 4 found* calc.** (I-1-8)*** + spinetoram (1: 1)  80 20 inventive spiromesifen 20  80 4  70 compound (I-1-2)/compound  4 + 20 found* calc.** (I-1-8)*** + spiromesifen (1: 5) 100 80 inventive compound (I-1-1)/compound 0.8 + 4   found* calc.** (I-1-7)*** + spiromesifen(1: 5)  90 73 inventive tebufenpyrad 4  40 compound (I-1-2)/compound 4 + 4 found* calc.** (I-1-8)*** + tebufenpyrad (1: 1)  90 40 inventive compound (I-1-1)/compound 4 + 4 found* calc.** (I-1-7)*** + tebufenpyrad (1: 1)  80 46 inventive tefluthrin 20  0 compound (I-1-2)/compound  4 + 20 found* calc.** (I-1-8)*** + tefluthrin (1: 5)  40  0 inventive *found = effect found **calc. = effect calculated by Colby's formula ***In the tested mixtures of compound (I-1-1)/compound (I-1-7) or compound (I-1-2)/compound (I-1-8), the compounds (I-1-1) and (I-1-2) were each present to an extent of approx. 85% or approx. 84%, and the compounds (I-1-7) and (I-1-8) each to an extent of approx. 15%. 

1. An active ingredient combination comprising a synergistically active combination of at least one compound of formula (I)

in which R¹ is hydrogen, amino, hydroxyl or in each case optionally mono- or polysubstituted identically or differently, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl or C₃-C₆-cycloalkyl, where the substituents may each independently be selected from halogen, cyano, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, (C₁-C₄-alkoxy)carbonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino and (C₁-C₄-alkyl)C₃-C₆-cycloalkylamino, R² is hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, C₁-C₆-alkoxycarbonyl or C₁-C₆-alkylcarbonyl, R³ is hydrogen or in each case optionally mono- or polysubstituted identically or differently, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₁₂-cycloalkyl, C₃-C₁₂-cycloalkyl-C₁-C₆-alkyl, where the substituents may each independently be selected from amino, C₃-C₆-cycloalkylamino, halogen, cyano, carboxyl, carbamoyl, nitro, hydroxyl, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylcarbonyl, C₃-C₆-trialkylsilyl or a saturated or partly saturated heterocyclic ring, an aromatic or heteroaromatic ring or a saturated, partly saturated or aromatic heterobicyclic ring, where the ring or ring system is optionally mono- or polysubstituted identically or differently by SF₅, halogen, cyano, nitro, hydroxyl, amino, carboxyl, carbamoyl, aminosulphonyl, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₆-haloalkyl, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-alkylsulphimino, C₁-C₄-alkylsulphimino-C₁-C₄-alkyl, C₁-C₄-alkylsulphimino-C₂-C₅-alkylcarbonyl, C₁-C₄-alkylsulphoximino, C₁-C₄-alkylsulphoximino-C₁-C₄-alkyl, C₁-C₄-alkylsulphoximino-C₂-C₅-alkylcarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylcarbonyl, C₃-C₆-trialkylsilyl, benzyl C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, or a 3- to 6-membered ring, where the ring may optionally be substituted by C₁-C₆-alkyl, halogen, cyano, nitro, halo(C₁-C₆)-alkyl, C₁-C₆-alkoxy or halo(C₁-C₆)-alkoxy, or R³ is C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylcarbonyl, C₁-C₆-alkylaminocarbonyl or di(C₁-C₆)alkylaminocarbonyl, or R³ is additionally a mono- or polysubstituted identically or differently, 5- or 6-membered aromatic or heteroaromatic ring, a 4, 5- or 6-membered partly saturated ring or saturated heterocyclic ring, or a saturated, partly saturated or aromatic heterobicyclic ring which may optionally contain one to three heteroatoms from the group of O, S and N, where the substituents are each independently selected from SF₅, halogen, cyano, nitro, hydroxyl, amino, carboxyl, carbamoyl, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₆-haloalkyl, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-alkylsulphimino, C₁-C₄-alkylsulphimino-C₁-C₄-alkyl, C₁-C₄-alkylsulphimino-C₁-C₅-alkylcarbonyl, C₁-C₄-alkylsulphoximino, C₁-C₄-alkylsulphoximino-C₁-C₄-alkyl, C₁-C₄-alkylsulphoximino-C₂-C₅-alkylcarbonyl, C₁-C₆-alkoxycarbonyl, C₁-C₆-alkylcarbonyl, C₃-C₆-trialkylsilyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, or a 3- to 6-membered ring, where the ring may optionally be substituted by C₁-C₆-alkyl, halogen, cyano, nitro, halo(C₁-C₆)-alkyl, C₁-C₆-alkoxy or halo(C₁-C₆)-alkoxy, R² and R³ may be joined to one another via two to six carbon atoms and form a ring which optionally additionally contains a further nitrogen, sulphur or oxygen atom and may optionally be mono- to tetrasubstituted by C₁-C₂-alkyl, C₁-C₂-haloalkyl, halogen, cyano, amino C₁-C₂-alkoxy or C₁-C₂-haloalkoxy, R², R³ together are additionally ═S(C₁-C₄-alkyl)₂, ═S(O)(C₁-C₄-alkyl)₂ R⁴ is hydrogen, halogen, cyano, nitro C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, SF₅, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, (C₁-C₄-alkoxy)imino, (C₁-C₄-alkyl)(C₁-C₄-alkoxy)imino, (C₁-C₄-haloalkyl)(C₁-C₄-alkoxy)imino or C₃-C₆-trialkylsilyl, or two R⁴ via adjacent carbon atoms form a ring which is —(CH₂)₃—, —(CH₂)₄—, —(CH₂)₅—, —(CH═CH—)₂—, —OCH₂O—, —O(CH₂)₂O—, —OCF₂O—, —(CF₂)₂O—, —O(CF₂)₂O—, —(CH═CH—CH═N)— or —(CH═CH—N═CH)—, two R⁴ via adjacent carbon atoms additionally form the following fused rings which are optionally mono- or polysubstituted identically or differently, where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₃-C₆-halocycloalkyl, halogen, C₁-C₆-alkoxy, C₁-C₄-alkylthio(C₁-C₆-alkyl), C₁-C₄-alkylsulphinyl(C₁-C₆-alkyl), C₁-C₄-alkylsulphonyl(C₁-C₆-alkyl), C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino or C₃-C₆-cycloalkylamino,

n is 0 to 3, R⁵ is C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₁-C₆-halocycloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, halogen, cyano, nitro or C₃-C₆-trialkylsilyl, Q_(X) is an optionally singly or multiply, identically or differently R⁷-substituted, aromatic or heteroaromatic 5- to 6-membered ring which may contain 1-3 heteroatoms from the group of N, S, O, A is optionally singly or multiply substituted —(C₁-C₆-alkylene)-, —(C₂-C₆-alkenylene)-, —(C₂-C₆-alkynylene)-, —R⁸—(C₃-C₆-cycloalkyl)-R⁸—, —R⁸—O—R⁸—, —R⁸—S—R⁸—, —R⁸—S(═O)—R⁸—, —R⁸—S(═O)₂—R⁸—, —R⁸—N(C₁-C₆-alkyl)-R⁸—, —R⁸—C═NO(C₁-C₆-alkyl)-R⁸, —CH[CO₂(C₁-C₆-alkyl)-, —R⁸—C(═O)—R⁸, —R⁸—C(═O)NH—R⁸, R⁸—C(═O)N(C₁-C₆-alkyl)-R⁸, —R⁸—C(═O)NHNH—R⁸—, —R⁸—C(═O)N(C₁-C₆-alkyl)-NH—R⁸—, —R⁸—C(═O)NHN(C₁-C₆-alkyl)-R⁸, —R⁸—O(C═O)—R⁸, —R⁸—O(C═O)NH—R⁸, —R⁸—O(C═O)N(C₁-C₆-alkyl)-R⁸, —R⁸—S(═O)₂NH—R⁸, —R⁸—S(═O)₂N(C₁-C₆-alkyl)-R⁸, —R⁸—S(C═O)—R⁸, —R⁸—S(C═O)NH—R⁸, —R⁸—S(C═O)N(C₁-C₆-alkyl)-R⁸, —R⁸—NHNH—R⁸, —R⁸—NHN(C₁-C₆-alkyl)-R⁸, —R⁸—N(C₁-C₆-alkyl)-NH—R⁸, —R⁸—N(C₁-C₆-alkyl)-N(C₁-C₆-alkyl)-R⁸, —R⁸—N═CH—O—R⁸, —R⁸—NH(C═O)O—R⁸, —R⁸—N(C₁-C₆-alkyl)-(C═O)O—R⁸, —R⁸—NH(C═O)NH—R⁸, —R⁸—NH(C═S)NH—R⁸, —R⁸—NHS(═O)₂—R⁸, R⁸—NH—R⁸, R⁸—C(═O)—C(═O)—R⁸, R⁸—C(OH)—R⁸, R⁸—NH(C═O)—R⁸, R⁸-Qz-R⁸, R⁸—C(═N—NR′₂)—R⁸, R⁸—C(═C—R′₂)—R⁸ or —R⁸—N(C₁-C₆-alkyl)S(═O)₂—R⁸, where the substituents may each independently be selected from halogen, cyano, nitro, hydroxyl, C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen-C₁-C₆-alkyl, amino, (C₁-C₆-alkyl)amino, di(C₁-C₆-alkyl)amino, C₃-C₆-cycloalkyl, where —(C₃-C₆-cycloalkyl)- in the ring may optionally contain 1 to 2 heteroatoms from the group of N, S, O, R⁸ is linear or branched-(C₁-C₆-alkylene)- or a direct bond, where two or more R⁸ are each independently linear or branched —(C₁-C₆-alkylene)- or a direct bond, for example R⁸—O—R⁸— is —(C₁-C₆-alkylene)-O—(C₁-C₆-alkylene)-, —(C₁-C₆-alkylene)-O—, —O—(C₁-C₆-alkylene)-, or —O—, where R′ is alkyl, alkylcarbonyl, alkenyl, alkynyl, which may optionally be mono- or poly-halogen-substituted, Qz is a 3- to 4-membered, partly saturated or saturated, or a 5- to 6-membered, partly saturated, saturated or aromatic ring or a 6- to 10-membered bicyclic ring system, where the ring or bicyclic ring system may optionally contain 1-3 heteroatoms from the group of N, S, O, where the ring or bicyclic ring system is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carbamoyl, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, (C₁-C₆-alkyl)carbonyl, (C₁-C₆-alkoxy)carbonyl, (C₁-C₆-alkyl)aminocarbonyl, di-(C₁-C₄-alkyl)aminocarbonyl, Q_(Y) is a 5- or 6-membered, partly saturated or saturated heterocyclic or heteroaromatic ring or an aromatic 8-, 9- or 10-membered fused heterobicyclic ring system, where the ring or ring system is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carboxyl, carbamoyl, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, (C₁-C₆-alkyl)carbonyl, (C₁-C₆-alkoxy)carbonyl, (C₁-C₆-alkyl)aminocarbonyl, di-(C₁-C₄-alkyl)aminocarbonyl, tri-(C₁-C₂)alkylsilyl, (C₁-C₄-alkyl)(C₁-C₄-alkoxy)imino, or where the substituents may each independently be selected from phenyl or a 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, R⁷ is hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₃-C₆-cycloalkoxy or

R⁹ is independently hydrogen, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, halogen, cyano, nitro, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio or C₁-C₄-haloalkylthio, p is 0 to 4, Z is N, CH, CF, CCl, CBr or Cl, and wherein the compound of formula (I) also can comprise an N-oxide and/or salt thereof (I), and at least one further insecticide and/or acaricide of the group (II) selected from: (1) Acetylcholinesterase (AChE) inhibitors, optionally carbamates, optionally alanycarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimethacarb, XMC and xylylcarb; or organophosphates, optionally acephate, azamethiphos, azinphos (-methyl, -ethyl), cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos (-methyl), coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos/DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, isofenphos, isopropyl O-(methoxyaminothiophosphoryl)salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, parathion (-methyl), phenthoate, phorate, phosalone, phosmet, phosphamidon, phoxim, pirimiphos (-methyl), profenofos, propetamphos, prothiofos, pyraclofos, pyridaphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, triclorfon and vamidothion. (2) GABA-gated chloride channel antagonists, optionally organochlorines, optionally chlordane and endosulfan (alpha-); or fiproles (phenylpyrazoles), optionally ethiprole, fipronil, pyrafluprole and pyriprole. (3) Sodium channel modulators/voltage-dependent sodium channel blockers, optionally pyrethroids, optionally acrinathrin, allethrin (d-cis-trans, d-trans), bifenthrin, bioallethrin, bioallethrin-S-cyclopentenyl, bioresmethrin, cycloprothrin, cyfluthrin (beta-), cyhalothrin (gamma-, lambda-), cypermethrin (alpha-, beta-, theta-, zeta-), cyphenothrin [(1R)-trans-isomers], deltamethrin, dimefluthrin, empenthrin [(EZ)-(1R)-isomers], esfenvalerate, eto-fenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, fluvalinate (tau-), halfenprox, imiprothrin, metofluthrin, permethrin, phenothrin [(1R)-trans-isomer], prallethrin, profluthrin, pyrethrins (pyrethrum), resmethrin, RU 15525, silafluofen, tefluthrin, tetramethrin [(1R)-isomers], tralomethrin, transfluthrin and ZXI 8901; or DDT; or methoxychlor. (4) Nicotinergic acetylcholine receptor agonists, optionally neonicotinoids, optionally acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid, thiamethoxam; or nicotine. (5) Allosteric acetylcholine receptor modulators (agonists), optionally spinosyns, optionally spinetoram and spinosad. (6) chloride channel activators, optionally avermectins/milbemycins, optionally abamectin, emamectin benzoate, lepimectin and milbemectin. (7) Juvenile hormone analogues, optionally hydroprene, kinoprene, methoprene; or fenoxycarb; pyriproxyfen. (8) Active ingredients with unknown or nonspecific mechanisms of action, optionally fumigants, optionally methyl bromide and other alkyl halides; or chloropicrin; sulphuryl fluoride; borax; tartar emetic. (9) Selective antifeedants, optionally pymetrozine; or flonicamid. (10) mite growth inhibitors, optionally clofentezine, diflovidazin, hexythiazox, etoxazole. (11) microbial disruptors of the insect gut membrane, optionally Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis, and BT plant proteins, optionally Cry1Ab, Cry1Ac, Cry1Fa, Cry2Ab, mCry3A, Cry3Ab, Cry3Bb, Cry34/35Ab1. (12) Oxidative phosphorylation inhibitors, ATP disruptors, optionally diafenthiuron; or organotin compounds, optionally azocyclotin, cyhexatin, fenbutatin oxide; or propargite; tetradifon. (13) Oxidative phosphorylation decouplers acting by interrupting the H proton gradient, optionally chlorfenapyr and DNOC. (14) Nicotinergic acetylcholine receptor antagonists, optionally bensultap, cartap (hydrochloride), thiocylam, and thiosultap (sodium). (15) Chitin biosynthesis inhibitors, type 0, optionally benzoylureas, optionally bistrifluron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron and triflumuron. (16) Chitin biosynthesis inhibitors, type 1, optionally buprofezin. (17) Moulting disruptors, optionally cyromazine. (18) Ecdysone agonists/disruptors, optionally diacylhydrazines, optionally chromafenozide, halofenozide, methoxyfenozide and tebufenozide. (19) Octopaminergic agonists, optionally amitraz. (20) Complex-III electron transport inhibitors, optionally hydramethylnone; acequinocyl; fluacrypyrim. (21) Complex-I electron transport inhibitors, optionally from the group of the METI acaricides, optionally fenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad, tolfenpyrad; or rotenone (Derris). (22) Voltage-dependent sodium channel blockers, optionally indoxacarb; metaflumizone. (23) Inhibitors of acetyl-CoA carboxylase, optionally tetronic acid derivatives, optionally spirodiclofen and spiromesifen; or tetramic acid derivatives, optionally spirotetramat. (24) Complex-IV electron transport inhibitors, optionally phosphines, optionally aluminium phosphide, calcium phosphide, phosphine, zinc phosphide; or cyanide. (25) Complex-II electron transport inhibitors, optionally cyenopyrafen. (28) Ryanodine receptor effectors, optionally diamides, optionally chlorantraniliprole and flubendiamide. and/or one or more further active ingredients with unknown mechanism of action, optionally amidoflumet, azadirachtin, benclothiaz, benzoximate, bifenazate, bromopropylate, chinomethionat, cryolite, cyantraniliprole (Cyazypyr), cyflumetofen, dicofol, diflovidazin, fluensulfone, flufenerim, flufiprole, fluopyram, fufenozide, imidaclothiz, imicyafos, iprodione, pyridalyl, pyrifluquinazon and iodomethane; and also preparations based on Bacillus firmus (I-1582, BioNeem, Votivo), further compounds such as dichloropropene, oil (optionally petroleum), metaldehyde, metam-sodium, and the following known active compounds: 3-bromo-N-{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl}-1-(3-chloropyridin-2-yl)-1H-pyrazole-5-carboxamide, 4-{[(6-bromopyrid-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one, 4-{[(6-fluoropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one, 4-{[(2-chloro-1,3-thiazol-5-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one, 4-{[(6-chloropyrid-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one, 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one, 4-{[(6-chloro-5-fluoropyrid-3-yl)methyl](methyl)amino}furan-2(5H)-one, 4-{[(5,6-dichloropyrid-3-yl)methyl](2-fluoroethyl)amino}furan-2(5H)-one, 4-{[(6-chloro-5-fluoropyrid-3-yl)methyl](cyclopropyl)amino}furan-2(5H)-one, 4-{[(6-chloropyrid-3-yl)methyl](cyclopropyl)amino}furan-2(5H)-one, 4-{[(6-chloropyrid-3-yl)methyl](methyl)amino}furan-2(5H)-one, {[1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ⁴-sulphanylidene}cyanamide and its diastereomers {[(1R)-1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ⁴-sulphanylidene}cyanamide (A) and {[(1S)-1-(6-chloropyridin-3-yl)ethyl](methyl)oxido-λ⁴-sulphanylidene}cyanamide (B) and sulfoxaflor and its diastereomers [(R)-methyl(oxido) {(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulphanylidene]cyanamide (A1) and [(S)-methyl(oxido) {(1S)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulphanylidene]cyanamide (A2), designated as diastereomer group A, [(R)-methyl(oxido) {(1S)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulphanylidene]cyanamide (B1) and [(S)-methyl(oxido) {(1R)-1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-λ⁴-sulphanylidene]cyanamide (B2), designated as diastereomer group B, and 11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1,4-dioxa-9-azadispiro[4.2.4.2]tetradec-11-en-10-one, 3-(4′-fluoro-2,4-dimethylbiphenyl-3-yl)-4-hydroxy-8-oxa-1-azaspiro[4.5]dec-3-en-2-one, 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulphinyl]phenyl}-3-(trifluoromethyl)-1H-1,2,4-triazol-5-amine, [(3S,4aR,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)oxy]-6,12-dihydroxy-4,12b-dimethyl-11-oxo-9-(pyridin-3-yl)-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-2H,11H-benzo[f]pyrano[4,3-b]chromen-4-yl]methyl cyclopropanecarboxylate, 2-cyano-3-(difluoromethoxy)-N,N-dimethylbenzenesulphonamide, 2-cyano-3-(difluoromethoxy)-N-methylbenzenesulphonamide, 2-cyano-3-(difluoromethoxy)-N-ethylbenzenesulphonamide, 4-(difluoromethoxy)-N-ethyl-N-methyl-1,2-benzothiazol-3-amine 1,1-dioxide, N-[1-(2,3-dimethylphenyl)-2-(3,5-dimethylphenyl)ethyl]-4,5-dihydro-1,3-thiazol-2-amine, {1′-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indole-3,4′-piperidin]-1(2H)-yl}(2-chloropyridin-4-yl)methanone, 3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4.5]dec-3-en-2-one, 3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-yl ethyl carbonate, 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine, (2,2,3,3,4,4,5,5-octafluoropentyl)(3,3,3-trifluoropropyl)malononitrile, (2,2,3,3,4,4,5,5-octafluoropentyl)(3,3,4,4,4-pentafluorobutyl)malononitrile, 8-[2-(cyclopropylmethoxy)-4-(trifluoromethyl)phenoxy]-3-[6-(trifluoromethyl)pyridazin-3-yl]-3-azabicyclo[3.2.1]octane, 2-ethyl-7-methoxy-3-methyl-6-[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)oxy]quinolin-4-yl methyl carbonate, 2-ethyl-7-methoxy-3-methyl-6-[(2,2,3,3-tetrafluoro-2,3-dihydro-1,4-benzodioxin-6-yl)oxy]quinolin-4-yl acetate, PF1364 (CAS Reg. No. 1204776-60-2), 5-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-(1H-1,2,4-triazol-1-yl)benzonitrile, 5-[5-(2-chloropyridin-4-yl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-(1H-1,2,4-triazol-1-yl)benzonitrile, 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}benzamide, 4-{[(6-chloropyridin-3-yl)methyl](cyclopropyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](ethyl)amino}-1,3-oxazol-2(5H)-one, 4-{[(6-chloropyridin-3-yl)methyl](methyl)amino}-1,3-oxazol-2(5H)-one, NNI-0711, 1-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-3-isobutylphenyl]-N-isobutyryl-3,5-dimethyl-1H-pyrazole-4-carboxamide, methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-chloro-3-methylbenzoyl]-2-methylhydrazinecarboxylate, methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-ethylhydrazinecarboxylate, methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methylbenzoyl]-2-methylhydrazinecarboxylate, methyl 2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-1,2-diethylhydrazinecarboxylate, methyl 2-[3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)benzoyl]-2-ethylhydrazinecarboxylate, (5RS,7RS;5RS,7SR)-1-(6-chloro-3-pyridylmethyl)-1,2,3,5,6,7-hexahydro-7-methyl-8-nitro-5-propoxyimidazo[1,2-a]pyridine, 2-{6-[2-(5-fluoropyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine, 2-{6-[2-(pyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine.
 2. An active ingredient combination according to claim 1, wherein R¹ is hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, cyano(C₁-C₆-alkyl), C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkyl, C₁-C₄-alkylsulphinyl-C₁-C₄-alkyl or C₁-C₄-alkylsulphonyl-C₁-C₄-alkyl, R² is hydrogen or C₁-C₆-alkyl, R³ is hydrogen or in each case optionally mono- or polysubstituted identically or differently, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₃-C₆-cycloalkyl, where the substituents may each independently be selected from halogen, cyano, carboxyl, carbamoyl, nitro, hydroxyl, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-alkoxycarbonyl, C₁-C₄-alkylcarbonyl or a phenyl ring or a 4, 5- or 6-membered, aromatic, partly saturated or saturated heterocyclic ring, where the phenyl ring or heterocyclic ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carboxyl, carbamoyl, NO₂, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, (C₁-C₆-alkyl)carbonyl, (C₁-C₆-alkoxy)carbonyl or R³ is C₂-C₄-alkoxycarbonyl, C₂-C₄-alkylcarbonyl, C₂-C₄-alkylaminocarbonyl or C₂-C₄ dialkylaminocarbonyl, or R³ is a phenyl ring, a 5- or 6-membered aromatic heterocyclic ring or a 4-, 5- or 6-membered partly saturated or saturated heterocyclic ring which may contain 1-3 heteroatoms from the group of N, S, O, where the phenyl ring or heterocyclic ring is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl, C₂-C₄-haloalkenyl, C₂-C₄-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carboxyl, carbamoyl, NO₂, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, C₁-C₄-alkylamino, di-(C₁-C₄-alkyl)amino, C₃-C₆-cycloalkylamino, (C₁-C₄-alkyl)carbonyl, (C₁-C₄-alkoxy)carbonyl, R⁴ is hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, halogen, cyano, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio or C₁-C₄-haloalkylthio, two adjacent R⁴ radicals are likewise —(CH₂)₃—, —(CH₂)₄—, —(CH₂)₅—, —(CH═CH—)₂—, —OCH₂O—, —O(CH₂)₂O—, —OCF₂O—, —(CF₂)₂O—, —O(CF₂)₂O—, —(CH═CH—CH═N)— or —(CH═CH—N═CH)—, n is 0, 1, 2, R⁵ is C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl, C₁-C₆-halocycloalkyl, C₂-C₆-alkenyl, C₂-C₄-haloalkenyl, C₂-C₄-alkynyl, C₂-C₄-haloalkynyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, halogen, cyano, nitro or C₃-C₆-trialkylsilyl, Q_(X) is an optionally singly or multiply, identically or differently R⁷-substituted 5-6 membered heteroaromatic ring which may contain 1-3 heteroatoms from the group of N, O, S, or is phenyl, A is optionally mono- or polysubstituted —(C₁-C₄-alkylene)-, —(C₂-C₄-alkenylene)-, —(C₂-C₄-alkynylene)-, —R⁸—(C₃-C₆-cycloalkyl)-R⁸—, —R⁸—O—R⁸—, —R⁸—S—R⁸—, —R⁸—S(═O)—R⁸—, —R⁸—S(═O)₂—R⁸—, —R⁸—NH—(C₁-C₄-alkyl)-, —R⁸—N(C₁-C₄-alkyl)-R⁸, —R⁸—C═NO(C₁-C₄-alkyl), —R⁸—C(═O)—R⁸, —R⁸—C(═S)—R⁸, —R⁸—C(═O)NH—R⁸, R⁸—C(═O)N(C₁-C₄-alkyl)-R⁸, —R⁸—S(═O)₂NH—R⁸, —R⁸—S(═O)₂N(C₁-C₄-alkyl)-R⁸, —R⁸—NH(C═O)O—R⁸, —R⁸—N(C₁-C₄-alkyl)-(C═O)O—R⁸, —R⁸—NH(C═O)NH—R⁸, —R⁸—NHS(═O)₂—R⁸, —R⁸—N(C₁-C₄-alkyl)S(═O)₂—R⁸, R⁸—NH—R⁸, R⁸—C(═O)—C(═O)—R⁸, R⁸—C(OH)—R⁸, R⁸-Qz-R⁸, where the substituents may each independently be selected from halogen, cyano, nitro, hydroxyl, C₁-C₆-alkyl, C₁-C₆-alkoxy or halo-C₁-C₆-alkyl, where Qz may have the general definitions specified above or the definitions specified below, Qz is a 3- to 4-membered, partly saturated or saturated, or a 5 to 6-membered, partly saturated, saturated or aromatic ring, where the ring may optionally contain 1-3 heteroatoms from the group of N, S, O, where the ring is optionally mono- or polysubstituted, identically or differently, and where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, R⁷ is C₁-C₆-alkyl or the radical

R⁷ is additionally C₃-C₆-cycloalkoxy, R⁹ is independently hydrogen, halogen, cyano, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkyl, C₁-C₄-haloalkoxy, C₁-C₄-haloalkylsulphonyl or (C₁-C₄-alkyl)C₁-C₄-alkoxyimino, p is 1, 2 or 3, Z is N, CH, CF, CCl, CBr or Cl, R⁸ is linear or branched —(C₁-C₄-alkylene)- or a direct bond, Q_(Y) is a 5- or 6-membered, partly saturated or saturated heterocyclic or heteroaromatic ring or an aromatic 8-, 9- or 10-membered fused heterobicyclic ring system, where the heteroatoms may be selected from the group of N, S, O, where the ring or the ring system is optionally mono- or polysubstituted identically or differently, and where the substituents may each independently be selected from hydrogen, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, carboxyl, carbamoyl, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-alkylsulphinyl, C₁-C₄-alkylsulphonyl, C₁-C₄-haloalkylthio, C₁-C₄-haloalkylsulphinyl, C₁-C₄-haloalkylsulphonyl, or where the substituents may each independently be selected from phenyl or a 5- or 6-membered heteroaromatic ring, where phenyl or the ring may optionally be mono- or polysubstituted identically or differently by C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₆-halocycloalkyl, halogen, cyano, nitro, hydroxyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy.
 3. An active ingredient combination according to claim 1, comprising at least one active ingredient of the formula (I-1)

in which R³ is hydrogen or in each case optionally mono- or polysubstituted identically or differently, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₁₂-cycloalkyl, C₃-C₁₂-cycloalkyl-C₁-C₆-alkyl, where the substituents may each independently be selected from halogen, amino, cyano, nitro, hydroxyl, C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₂-C₆-alkoxycarbonyl, C₁-C₆-alkylcarbonyl C₃-C₆-cycloalkylamino or a 5- or 6-membered heteroaromatic ring, R⁴ is halogen, cyano or methyl, R⁵ is methyl or chlorine, Z is N, CCl or CH, Qy is an optionally mono- or polysubstituted 5- or 6-membered heteroaromatic ring from the group of Q-36 to Q-40, Q43, Q-58 to Q-59, Q62, Q63, an aromatic 9-membered fused heterobicyclic ring system Q-54 to Q-56 and a 5-membered heterocyclic ring Q-60 to Q-61, where the substituents may each independently be selected from C₁-C₃-alkyl, C₁-C₃-haloalkyl, C₁-C₂-alkoxy, halogen, cyano, hydroxyl, nitro or C₁-C₂-haloalkoxy, where the compound of the formula (I-1) may be present in the form of a salt and/or N-oxide,

and at least one insecticide and/or acaricide of said group (II).
 4. An active ingredient combination according to claim 3, comprising a mixture of compounds of the formula (I) or (I-1) in which Qy is Q62 and Q63, where the ratio of a compound of the formula (I) or (I-1) in which Qy is Q62 to a compound of the formula (I) or (I-1) in which Qy is Q63 is 80:20 to 99:1.
 5. An active ingredient combination according to claim 3, comprising a mixture of compounds of the general formula (I) or (I-1), in which Qy is Q58 and Q59, where the ratio of a compound of the formula (I) or (I-1) in which Qy is Q58 to a compound of the formula (I) or (I-1) in which Qy is Q59 is 80:20 to 99:1.
 6. An active ingredient combination according to claim 3, wherein R³ is hydrogen or in each case optionally mono- or polysubstituted identically or differently, C₁-C₆-alkyl, C₁-C₆-alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, C₃-C₆-cycloalkyl-C₁-C₆-alkyl, where the substituents may each independently be selected from halogen, cyano, amino, hydroxyl, C₁-C₆-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₃-C₆-cycloalkyl, a 5 or 6-membered heteroaromatic ring containing 1-2 heteroatoms from the group of N, O, S, where no two oxygen atoms in the ring are adjacent, R⁴ is halogen, cyano or methyl, R⁵ is methyl, Z is N or CH, Q_(Y) is an optionally mono- or polysubstituted identically or differently, heteroaromatic ring from the group of Q-37, Q-38, Q-39, Q-40, Q43, Q-58, Q-59, Q62 and Q63, and a 5-membered heterocyclic ring Q-60 where the substituents may each independently be selected from methyl, ethyl, cyclopropyl, tert-butyl, chlorine, fluorine, iodine, bromine, cyano, nitro, difluoromethyl, trifluoromethyl, pentafluoroethyl, heptafluoro-n-propyl and heptafluoroisopropyl.
 7. An active ingredient combination according to claim 1, wherein the ratio of a compound or compounds of formula (I) to a compound or compounds of group (II) is 625:1 to 1:625.
 8. An active ingredient combination according to any of claim 1, wherein the active ingredient of group (II) is at least one selected from acrinathrin alpha-cypermethrin betacyfluthrin cyhalothrin cypermethrin deltamethrin esfenvalerat etofenprox fenpropathrin fenvalerate flucythrinate lambda-cyhalothrin gamma-cyhalothrin permethrin tau-fluvalinate transfluthrin zeta-cypermethrin cyfluthrin bifenthrin tefluthrin eflusilanate fubfenprox pyrethrin resmethrin imidacloprid acetamiprid thiamethoxam nitenpyram thiacloprid dinotefuran clothianidin imidaclothiz chlorfluazuron diflubenzuron lufenuron teflubenzuron triflumuron novaluron flufenoxuron hexaflumuron bistrifluoron noviflumuron buprofezin cyromazine methoxyfenozide tebufenozide halofenozide chromafenozide endosulfan fipronil ethiprole pyrafluprole pyriprole flubendiamide chlorantraniliprole (Rynaxypyr) cyazypyr emamectin emamectin benzoate abamectin ivermectin milbemectin lepimectin tebufenpyrad fenpyroximate pyridaben fenazaquin pyrimidifen tolfenpyrad dicofol cyenopyrafen cyflumetofen acequinocyl fluacrypyrin bifenazate diafenthiuron etoxazole clofentezine spinosad triarathen tetradifon propargite hexythiazox bromopropylate chinomethionat amitraz pyrifluquinazone pymetrozine flonicamid pyriproxyfen diofenolan chlorfenapyr metaflumizone indoxacarb chlorpyrifos spirodiclofen spiromesifen spirotetramat pyridalyl spinetoram acephate triazophos profenofos fenamiphos 4-{[(6-chloropyrid-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-one cadusaphos carbaryl carbofuran ethoprophos thiodicarb aldicarb metamidophos methiocarb sulfoxaflor Bacillus firmus I-1582 dichloropropene dimethoate metaldehyde methomyl cartap oil (optionally petroleum) chloropicrin carbosulfan dichlorvos metam-sodium phoxim monocrotophos oxamyl methidathion fenitrothion terbufos fluensulfone imicyafos 11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1,4-dioxa-9-azadispiro[4.2.4.2]tetradec-11-en-10-one 2-{6-[2-(5-fluoropyridin-3-yl)-1,3-thiazol-5-yl]pyridin-2-yl}pyrimidine
 9. An active ingredient combination according to claim 1, wherein the compound of formula (I) comprises a compound and/or salt and/or N-oxide thereof selected from the group consisting of the compounds (I-1-1) to (I-1-60)


10. An active ingredient combination according to claim 9, comprising a mixture of compounds selected from the group consisting of I-1-1-/1-1-7, 1-1-2/1-1-8, 1-1-3/1-1-9, I-1-4/1-1-10, I-1-5/1-1-11, I-1-6/1-1-12, I-1-13/I-1-1-19, 1-1-14/1-1-20, I-1-15/I-1-21, I-1-16/I-1-22, I-1-17/I-1-23, I-1-18/I-1-24, 1-1-25/1-1-31, 1-1-26/1-1-32, I-1-27/I-1-33, 1-1-28/1-1-34, I-1-29/I-1-35, I-1-30/I-1-36, 1-1-37/1-1-43, 1-1-38/1-1-44, I-1-39/I-1-45, I-1-40/I-1-46, I-1-41/I-1-47, I-1-42/I-1-48, I-1-49/I-1-55, I-1-50/I-1-56, I-1-51/I-1-57, I-1-52/I-1-58, I-1-53/I-1-59, I-1-54/I-1-60.
 11. An agrochemical composition comprising an active ingredient combination according to claim 1, and at least one extender and/or surfactant.
 12. An active ingredient combination according to claim 1 suitable for control of animal pests.
 13. Method for controlling animal pests, comprising allowing an active ingredient combination as defined in claim 1 to act on animal pests and/or their habitat.
 14. Process for producing agrochemical compositions, comprising mixing an active ingredient combination as defined in claim 1 with at least one extender and/or surfactant. 